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The lung is among the deadliest sites of breast cancer metastasis. Previous work from our 
laboratory demonstrated that aggressive CD44-expressing breast cancer cells preferentially 
metastasize to the lung in vivo, and observed the presence of multiple CD44-interacting 
proteins in the lung including E-, L- and P-selectin. We hypothesized that lung-derived 
selectins promote breast cancer migration and/or growth via interactions with CD44. Using an 
ex vivo model of the soluble lung-microenvironment, we demonstrate that lung-derived 
selectins enhance in vitro migration but not proliferation of breast cancer cells. Co-
immunoprecipitation experiments reveal that CD44 expressed by breast cancer cells in vitro 
interacts with soluble selectins. The mechanism underlying the pro-migratory effect of lung-
derived selectins is independent of ezrin/radixin/moesin (ERM) or CREB phosphorylation. 
Future studies should be aimed at elucidating mechanisms by which lung-derived selectins 
exert their pro-migratory function and whether these proteins can be targeted therapeutically 
to reduce lung metastasis of breast cancer. 
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Cancer is a family of diseases hallmarked by uncontrolled cell growth and 
proliferation. This dysregulation often occurs as a result of normal cells accumulating 
multiple genetic mutations over time1. Mutations relevant to cancer development often 
occur in either oncogenes or tumour suppressor genes. Oncogenes are genes that when 
activated through gain-of-function mutations will promote cancer cell growth and 
division2. In contrast, tumour suppressor genes are negative regulators of cell growth and 
overall malignancy; their inactivation through loss-of-function mutations leads to 
increased cell proliferation and survival. As cancers progress, the cells gain the 
characteristic abilities to self-sustain proliferative signaling, replicate infinitely, resist cell 
death, induce angiogenesis, activate metastasis and avoid destruction by the immune 
system3. A mass of these cancerous cells is referred to as a tumour, which can be either 
benign or malignant in nature.4 Benign tumours remain confined to their original location 
and are usually non-life-threatening. In contrast, a malignant tumour can invade 
surrounding tissue and also spread to distant regions of the body; these are life-threatening. 
1.2 Breast Tissue and Breast Cancer 
The principal structure of the breast is the mammary gland5. It is composed of milk-
producing cuboidal epithelial cell-lined acini organized into lobules, with each having a 
lactiferous duct responsible for transporting the milk to the nipple for ejection. Breast 
cancer is any primary tumour formation originating from the breast tissue, most commonly 
the milk-producing lobules and the ducts which transport it6. These structures are 
susceptible to cancerous transformation in part because of the cycling stimulation of 
estrogen and progesterone on the proliferation of breast epithelial cells7. Over time, this 
leads to increased cell turnover and accumulation of genetic defects8. 
There are multiple schemas by which breast cancer can be classified, one of which 
is based on histopathology. This takes into consideration the structure from which the 
tumour cells originated and whether they have remained confined to their site of origin, i.e. 
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have not invaded into the surrounding tissue structures. Primary breast tumours which 
originate from the lobules and are confined to their site of origin are classified as lobular 
carcinoma in situ9. Those originating from the ductal epithelium and have not invaded into 
surrounding tissue are classified as ductal carcinoma in situ. At the in situ stage, the 
tumours are non-invasive and can be effectively treated with surgery, hormone therapy 
and/or radiation therapy. The five-year survival rate for affected patients is 98.6%10. 
However, once the cancer has become invasive and has begun infiltrating the surrounding 
tissue, the prognosis worsens. If the invasion is allowed to persist, breast cancer can spread, 
or metastasize, to distant organs.  
An additional and more detailed system used to stratify breast cancer cases is based 
on molecular subtype. Cases can be categorized into one of four groups: luminal A, luminal 
B, HER2-enriched and basal-like (triple-negative; TN). Grouping into each group is based 
on the combination of their hormone receptor status (estrogen [ER] and progesterone [PR]), 
HER2 (human epidermal growth factor receptor 2) status and proliferation index (Ki-67). 
Luminal A is the most commonly diagnosed subtype of breast cancer and is characterized 
by ER+/PR+/HER2- and a low rate of proliferation11. Diagnosed patients show good 
prognosis and survival rates as they respond well to hormone therapy. Luminal B is a more 
aggressive phenotype than luminal A and is identified based on an ER+/PR+ phenotype 
with either a high proliferation rate and/or HER2+ status. Survival rates are slightly lower 
than those observed in luminal A breast cancer patients, but still fairly high as these patients 
also respond well to hormone therapy. HER2-enriched tumours are hormone receptor 
negative (ER-/PR-) and HER2+. Generally, these tumours are associated with a poorer 
prognosis and higher incidence of metastasis relative to the luminal A/B subtypes12. These 
patients are treated with HER2-targeting agents such as Herceptin (trastuzumab) that can 
directly interfere with HER2 receptor signaling and subsequently reduce cancer cell growth 
and tumour progression13. The only subtype for which no targeted therapies currently exist 
is basal-like/TN, which are characterized by an ER-/PR-/HER2- status and are highly 
aggressive in nature. The average expected 5-year survival rate for these patients is 
approximately 26%, as TN breast tumours commonly metastasize to essential 




Metastasis is a complex process through which secondary tumours in distant organ 
sites can occur7. The metastatic cascade (Figure 1) can initiate once the primary tumour 
has developed its own blood supply through angiogenesis to support its metabolic 
demands8. Not only do these newly formed blood vessels increase the growth potential of 
the primary tumour, but they also create a means through which cancer cells can spread to 
other organs. The first step of the metastatic cascade is intravasation, a process by which 
tumour cells that have dissociated from the solid tumour will cross the endothelium and 
enter the blood circulatory system15. Tumour cells can enter the circulatory system directly 
or indirectly via the lymphatic system. Once in circulation, tumour cells must survive the 
shear stress of blood flow and evade destruction by immune cells before they can arrest in 
the capillary beds of distant organs. At these sites, tumour cells must extravasate in order 
to exit the circulatory system and enter the secondary organ. These tumour cells will only 
establish a metastatic tumour if they are able to survive and proliferate in the organ's 
microenvironment.  
In the metastatic breast cancer setting, current therapies are largely ineffective and 
5-year survival rates are approximately 26%6, 7. The majority of breast cancer-related 
deaths can be attributed to metastasis, as tumours in the brain, lung, liver and bone can 
impair essential physiological functions and eventually lead to death16. In comparison, 
primary tumours when contained within the breast are non-life threatening. For example, 
patients with metastatic tumours in the lung present clinically with pain, hemoptysis, 
pleural effusions and/or pulmonary dysfunction17. A pleural effusion is the build-up of fluid 
in the pleural space around the lungs and can negatively affect breathing and gas 
exchange18, 19. Unfortunately, pleural effusions caused by a malignancy are incurable and 
treatments are focused on palliative care. The median survival from clinical recognition of 
a malignant pleural effusion is 4 months20. The high mortality associated with metastasis 









Figure 1. The metastatic cascade. Tumour cells that have dissociated from the primary 
tumour have the potential to spread to distant organs. This occurs through four key steps, 
which begins with intravasation. Intravasation is the process by which cells traverse the 
endothelium and enter the systemic circulation. These cells then circulate throughout the 
body until they reach a location where they will exit the circulation and enter the organ’s 
parenchyma. This step is known as extravasation. If the organ microenvironment possesses 
ideal conditions for growth of the tumour cells, they may grow and proliferate to form 




1.4 Metastatic Organ Tropism 
Clinically, it has been previously observed that breast cancer metastasizes most 
often to the lung, bone, liver, brain and lymph nodes21. This phenomenon of preferential 
metastasis to specific organs has been observed in different types of cancer and is termed 
organ tropism22.  The two main theories that have been proposed to explain organ tropism 
are Stephen Paget’s “seed and soil” hypothesis and James Ewing’s mechanical arrest 
theory21. In 1889, Paget hypothesized that organ-specific patterns of metastasis were a 
result of cancer cells (“seeds”) requiring specific organ microenvironmental conditions at 
secondary sites (“soil”) to be able to survive and grow23. This was proposed based on his 
observation of a non-random pattern of metastasis to specific visceral organs and bone 
from the autopsy records of 735 female breast cancer patients. James Ewing proposed an 
alternative theory forty years later, postulating that organ tropism could be accounted for 
by blood flow patterns14. Specifically, his theory emphasized that cancer cells would 
mechanically arrest in the first capillary bed they encountered. However, his theory could 
not explain why some organs that are served by only a small fraction of the blood flow 
(e.g. brain and bone) are disproportionately more affected by metastasis, while other organs 
that receive considerable blood flow (e.g. heart) are uncommonly involved in the 
colonization of secondary tumours24.  
It is likely that these two theories operate in concert to allow tumour cells to reach 
secondary organ sites and form metastases. Based on these theories, using the lung as an 
example, breast cancer cells that have dissociated from the primary tumour and invaded 
nearby capillaries would be carried within venous blood to the heart and then circulated to 
the lungs, where tumour cells would mechanically arrest in the first capillary bed they 
encounter in the lungs. Secondary tumour formation could then occur; but would be 
dependent on compatible characteristics of the breast cancer cells (the “seed”) and 
supporting factors produced by the lung microenvironment (the “soil”)25. 
1.4.1 The “Seed” – Breast Cancer Cells 
Studies carried out by Joan Massagué’s group have demonstrated the influence of 
breast cancer cell gene expression profiles on organ-specific metastasis. Using three 
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different models of metastasis and multiple rounds of in vivo selection, they generated 
brain-seeking26, bone-seeking27 and lung-seeking28 variants of the aggressive TN human 
breast cancer cell line MDA-MB-231. Transcriptome analysis demonstrated that each 
variant had a unique gene expression profile. When the data from the lung-seeking variant 
was compared against patient breast tumour samples and patient incidences of lung 
metastasis, it was found that the expression pattern of 18 univariately significant genes was 
enough to define a lung metastasis signature (Table 1)28. In further studies, this signature 
was shown to be associated with breast cancer relapse to the lung, but not to the bones, 
liver or lymph nodes26, 29. There was a weak association of the lung metastasis signature 
with relapse to the brain, likely because six of the 18 genes are also found in the brain 
metastasis signature26. These genes comprising the lung metastasis signature encode for a 
variety of different protein classes; including extracellular receptors, adhesion receptors, 
chemokines, secreted proteases and transcriptional regulator proteins28. Overall, their 
findings highlight the relationship between breast cancer cells, their genetic signature and 
the organ microenvironments to which they preferentially metastasize. However, there are 
other characteristics that have used to define a subset of cancer cells with an overall 
increased ability for metastasis. 
1.4.1.1 “Stem-Like” Breast Cancer Cells  
Cancer stem cells (CSCs) represent a small subpopulation of cancer cells found 
within solid tumours, and they have an increased ability for both primary tumour formation 
and metastasis30, 31. Their existence was first validated by John Dick and colleagues in 1997 
based on findings in human acute myeloid leukemia that only a subset of cells was capable 
of inducing leukemia32. CSCs are defined as cells that have both the ability to self-renew 
and give rise to a wide range of differentiated cells that comprise a tumour33. In the context 
of breast cancer, CSCs were first isolated based on a CD44+/CD24- phenotype34. As few as 
100 CD44+/CD24- cells when injected into the mammary fat pad of mice were able to form 
tumours. This contrasts with other phenotypes, where as many as 10,000 cells when 
injected into the mammary fat pad were unable to form tumours. Breast cancer stem cells 
have since then been further defined to include high activity of the aldehyde dehydrogenase 
1 (ALDH1)35. This intracellular enzyme oxidizes aldehydes to protect stem cells and its   
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Table 1. Breast cancer lung metastasis signature  
 
   Adapted from Minn, A. J. et al, Nature 2005, 436 (7050), 518-24
28
 
Symbol Gene Name 
Also found in 
brain metastasis 
signature26 
ANGPTL4 Angiopoietin-like 4 + 
FSCN1 
Fascin homologue 1, actin-bundling protein 
(Strongylocentrotus purpuratus) 
+ 
LTBP1 Latent transforming growth factor beta binding protein 1 + 
MMP1 Matrix metalloproteinase 1 (interstitial collagenase) + 
PTGS2 
Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
+ 
RARRES3 Retinoic acid receptor responder (tazarotene induced) 3 + 
C10orf116 Chromosome 10 open reading frame 116 – 
CXCL1 
Chemokine (C-X-C motif) ligand 1 (melanoma growth-
stimulating activity, alpha) – 
CXCR4 Chemokine (C-X-C motif) receptor 4 – 
EREG Epiregulin – 
ID1 
Inhibitor of DNA binding 1, dominant-negative helix–loop–
helix protein – 
KRTHB1 Keratin, hair, basic, 1 – 
KYNU Kynureninase (L-kynurenine hydrolase) – 
LY6E Lymphocyte antigen 6 complex, locus E – 
MAN1A1 Mannosidase, alpha, class 1A, member 1 – 
NEDD9 
Neural precursor cell expressed, developmentally 
downregulated 9 – 
TNC Tenascin C (hexabrachion) – 
VCAM1 Vascular cell adhesion molecule 1 – 
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activity is also associated with early stem cell differentiation36, 37. Functionally, it has been 
shown that if cells are isolated based on an ALDHhi/CD44+/CD24- phenotype, as few as 20 
cells transplanted into a mammary fat pad could generate a tumour35. Previous studies by 
our laboratory provided the first evidence of the ALDHhi/CD44+/CD24- breast cancer cell 
subpopulation as metastasis-initiating cells38. In vitro, these cells demonstrated increased 
growth, adhesion, colony formation, migration and invasion relative to their 
ALDHlowCD44low counterparts. They also demonstrated that ALDHhi/CD44+/CD24- 
human breast cancer cells are both more tumorigenic and metastatic in vivo than 
ALDHlowCD44- cells, with a particular propensity to metastasize to the lung. Together with 
Massagué’s observations, these studies highlight the existence of properties intrinsic to 
certain breast cancer cells (the “seeds”) that enhance their metastatic ability to different 
organ sites. In particular, the role that CD44 may play in enhancing the abilities of 
ALDHhiCD44+ breast cancer cells to interact with their microenvironment during 
metastasis may relate to its function as a cell surface receptor. 
1.4.1.2 Cluster of Differentiation 44 (CD44) Receptor 
The cluster of differentiation 44 receptor (CD44), belongs to a family of cell 
adhesion molecules with well-established functions in mediating cell-cell and cell-
extracellular matrix (ECM) adhesion and communication39. There are over 20 different 
isoforms of this transmembrane receptor, and they vary from 80-200 kDa in size. This 
variance in size is generated from differences in RNA splicing and post-translational 
protein modifications40. CD44 is encoded by a 20 exon-containing gene. Eight of the exons 
are constant and found in all isoforms, while others are inserted in variants. Inclusion of 
additional exons lengthens the amino-terminal extracellular region of the receptor and 
exposes new binding sites for both posttranslational modifications and ligand binding41. 
The cytoplasmic C-terminal region of the receptor does not differ between variants and 
plays an important role in receptor signal transduction42, 43. Studies have shown that CD44 
is involved in the regulation of cell growth, differentiation, survival and motility44. Some 
of these processes are regulated by CD44 at the transcriptional level as the intracellular 
domain of CD44 can be cleaved to release a fragment capable of acting as a transcriptional 
factor45. Others such as motility have been shown to be regulated at least in part through 
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interactions of CD44 with members of the Band 4.1 superfamily of proteins, including 
ezrin, radixin and moesin (ERM)46. ERM proteins allow CD44 to exert its influence on cell 
shape and migration by crosslinking the actin cytoskeleton to CD44. The affinity of ERM 
proteins for CD44 is dependent on their phosphorylation status at key tyrosine and 
threonine residues. The phosphorylation is mediated by either growth factor receptors such 
as MET47, a receptor tyrosine kinase, or downstream proteins such as protein kinase Cα48.  
Under normal conditions, CD44 is widely distributed and its expression has been 
observed in the epithelial tissue of many different organs, including but not limited to lung, 
liver, bone marrow, mammary gland and kidneys49. The actions of CD44 in each tissue are 
likely related to the isoforms of the receptor present and ligands present, as not all variants 
have the same affinity for CD44 ligands. CD44 ligands that have previously been identified 
include hyaluronan50, osteopontin51, serglycin52, E-, L- and P-selectin53-55. The standard 
isoform (CD44S) has been shown to be important in the context of breast cancer. It has 
specifically been shown to be involved in breast cancer cell adhesion, migration and 
invasion, and is the isoform utilized in isolation and functional analysis of stem-like breast 
cancer cells based on either the CD44+/CD24- or ALDHhi/CD44+/CD24- phenotype56, 57.  
1.4.2 The “Soil” – Organ Microenvironments 
The influence of organ microenvironments (the “soil”) on tumour growth and 
metastasis has been previously reported based on clinical observations of cancer patients, 
in vitro experiments, and experimental murine models of cancer58, 59.  These studies 
illustrate that metastasis is often largely independent of an organ's vascular anatomy, blood 
flow or the number of tumour cells delivered to an organ site. Instead, the potential for 
successful secondary tumour formation and growth is heavily dependent on the interactions 
between organ microenvironments and tumour cells.  
The role of the soluble organ microenvironment in promoting breast cancer 
metastatic behavior has been previously examined by our lab25, 60-62. We developed an ex 
vivo model system to study the influence of organ-derived soluble factors on breast cancer 
cell migration and proliferation. The specific organs that were examined represented the 
five most common clinical sites of breast cancer metastasis, including lung, bone, liver, 
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brain and lymph nodes. These different organs were aseptically harvested from female 
nude athymic mice and cultured to generate organ conditioned media (CM). Using this 
model, Chu and colleagues demonstrated that human breast cancer cells exhibit cell line-
specific and organ-specific chemotactic and proliferative patterns that reflect their in vivo 
patterns of metastasis25. Notably, all 4 cell lines showed increased migration towards lung-
conditioned media relative to basal media, and 2 of the 4 cell lines showed increased 
proliferation in lung-conditioned media. This suggested that specific soluble factors within 
the lung microenvironment may be promoting the metastatic behaviour of breast cancer 
cells. Using a protein array, Chu identified 70 different soluble proteins that were found in 
the lung-CM. Many of these factors had been previously implicated in metastasis, 
including 5 CD44 ligands (osteopontin, basic fibroblast factor, and E-, L-, and P-selectin) 
as well as proteins/pathways such as epiregulin (EREG), OPN, and urokinase-type 
plasminogen activator (uPA) that had been previously associated with lung metastasis of 
breast cancer by Massagué’s group25, 28. The focus of this thesis is to further investigate the 
role of lung-derived E-, L-, and P-selectin in breast cancer metastatic behaviour.  
1.5 Selectins 
The selectins are a three-member family of type I cell-surface glycoproteins that 
function to mediate adhesions between leukocytes, platelets and the endothelium63. 
Structurally, selectins consist of a N-terminal lectin domain, followed by an epidermal 
growth factor domain, two to nine consensus repeats (two in L-selectin, six in E-selectin 
and nine in P-selectin), a transmembrane domain and a C-terminal cytoplasmic domain 
(Figure 2A)64. There is high sequence homology between E-, L- and P-selectin in all 
domains except the transmembrane and cytoplasmic domains. The lectin domain 
recognizes specific carbohydrates on target proteins to which selectins bind.  
Selectins differ in terms of their expression. L-selectin is constitutively expressed 
on the surface of most leukocytes65. P-selectin is stored intracellularly in granules in 







Figure 2. Membrane-bound selectins and the generation of their soluble forms. A) 
The general structure of selectin proteins consists of a N-terminal lectin domain, an 
epidermal growth factor (EGF) domain, followed by 2-9 consensus repeats, a 
transmembrane domain and a C-terminal cytoplasmic domain. B) Soluble forms of each 
selectin are generated through proteolytic cleavage from the cell surface. i) E-selectin is 
expressed on endothelial cells and is cleaved by an unknown mechanism into soluble E-
selectin. ii) P-selectin is expressed on the surface of both endothelial cells and platelets. Its 
cleavage from the cell surface is mediated by tumor necrosis factor alpha converting 
enzyme. iii) L-selectin is expressed on the surface of leukocytes and its cleavage is 





which P-selectin is rapidly translocated to the cell surface66. E-selectin is only expressed 
on the surface of activated endothelial cells. Its expression is increased hours after cell 
stimulation with pro-inflammatory mediators as E-selectin is not stored intracellularly in 
granules, rather it is produced de novo63, 67 
Selectins exist not only as membrane bound proteins but also as cleaved soluble 
proteins. Cleavage is likely proximal to the membrane spanning domain as it has been 
noted that there is a slight difference in molecular weight between the membrane-bound 
and soluble forms (Figure 2B)68-70. In vitro studies suggest that soluble E-, L- and P-
selectin remain functionally active after having been shed from the cell surface71-73. L-
selectin and P-selectin cleavage occurs following cell activation, and the proteases 
responsible for generating the soluble forms include TNF-alpha converting enzyme and 
matrix metalloproteinase 9 (MMP-9), respectively65, 74. With respect to E-selectin, the 
protease responsible for generating the soluble form has not yet been identified. However, 
it is known that E-selectin is shed from the cell surface under normal conditions and that 
the rate of E-selectin cleavage is increased following stimulation of endothelial cells by 
cytokines70.  
1.5.1 Clinical Relevance of Selectins in Cancer 
Of the three selectins, E-selectin is the most well-studied in the context of cancer. 
It has been clinically observed that the serum levels of E-selectin are significantly higher 
in patients with advanced breast cancer that have distant metastasis when compared to 
either earlier stage patients with localized primary breast tumors or those who have 
completed initial treatment and have no evidence of relapse at one year post-diagnosis75-77. 
Similarly, other studies have demonstrated that high E-selectin serum concentrations in 
patients with breast cancer are prognostic for reduced progression-free and overall survival 
relative to those with low serum concentrations of E-selectin77, 78. In addition to these 
prognostic studies of serum E-selectin, others have examined the effect of E-selectin 
polymorphisms on breast cancer prognosis. They observed that a genetic mutation resulting 
in the substitution of serine 128 by arginine increases the affinity of E-selectin for its 
binding partners79. Clinically, patients homozygous for this mutation have poorer survival 
than patients who are homozygous for the wild-type allele80.  
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For L-selectin, it has not been reported in the literature whether levels of the protein 
in the blood are affected by breast cancer. However, in acute myeloid leukemia, one study 
noted that patients with elevated plasma L-selectin levels (defined as a value three standard 
deviations above the average of healthy control individuals) had lower probabilities of 
achieving complete cancer remission and had reduced progression-free and overall 
survival81. In another study that examined patients with high-grade muscle invasive 
bladder cancer, higher concentrations of L-selectin were found in the serum of patients 
with metastatic vs. nonmetastatic stages of the disease82. Similarly, soluble P-selectin has 
been detected in increased amounts in the sera of breast cancer and colon cancer relative 
to healthy controls, however no significant differences were noted in P-selectin 
concentrations between stages of each cancer83, 84. Although a mechanistic understanding 
of selectins in the clinical setting of breast cancer is somewhat limited, studies using 
experimental models have provided more detailed evidence of the functional importance 
of selectins in cancer.  
1.5.2 Experimental Evidence of the Role of Selectins in Metastasis 
Animal models to represent the deficiency of one or more selectins have previously 
been generated through gene knockout. Phenotypically, selectin deficiencies in single 
selectins do not cause infertility or embryonic lethality. However, certain combinations of 
deficiencies can cause health issues. Mice deficient in both E- and P-selectin (EP-/-) or E-, 
L- and P-selectin (ELP-/-) were more likely to develop mucocutaneous infections that 
eventually lead to death. This may be caused by alterations in leukocyte homeostasis and 
recruitment, as supported by Robinson and colleagues. They demonstrated that peripheral 
blood leukocyte levels were significantly elevated in EP-/- (1.7 fold relative to wild-type) 
and ELP-/- mice (2.4 fold), and to a lower extent in mice deficient in P- and L-selectin (PL-
/-) (1.2 fold)85. This leukocytosis was likely caused by impairments of leukocyte 
recruitment to sites of inflammation and infection, as they also demonstrated that 
neutrophil influx in EP-/-, PL-/- and ELP-/- mice to sites of chemically-induced peritonitis 
was less than one-third of that observed in wild-type mice. 
 While these deficiencies may negatively affect immune cell recruitment, evidence 
suggests that they may also be advantageous to disruption of metastasis. In an experimental 
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model of spontaneous breast cancer metastasis, the number of lung metastasis foci was 
significantly lower in E-/- and EP-/- mice than wild-type86. Similar studies have been 
conducted to examine the influence of L- and P-selectin single or double knockout on lung 
metastasis in other tumour types including colon carcinoma. P-/- mice and L-/- mice 
demonstrated lower lung metastatic burden relative to the wild-type control87. Relative to 
the single-knockout mice, the lung metastatic burden was significantly lower in PL-/- mice, 
suggesting a synergistic effect.  
  Our lab has previously identified the presence of L-,E, and P-selectin in lung 
conditioned media. Chu and Xia et al examined the effect of depleting L-selectin from 
lung-conditioned media on breast cancer cell migration and proliferation. They observed 
that L-selectin was not involved in cell proliferation of TN breast cancer cells but did affect 
cell migration/ invasion25. However, the role of E- and P-selectin in mediating breast cancer 
metastatic behavior as well as the mechanisms by which this may occur require further 
investigation, and that is the overall focus of this thesis.  
2 STUDY RATIONALE  
Breast cancer is the leading cancer diagnosis and second leading cause of cancer-
related death among Canadian women. Current therapies are highly effective in treating 
breast cancer localized to the breast. However, these therapies are largely ineffective in the 
metastatic setting, and metastasis accounts for the majority of breast cancer patient deaths. 
Previous studies from our lab and others have demonstrated that breast cancer cells which 
express high levels of CD44 are metastatic and preferentially spread to the lung. In 
accordance with Paget’s “seed and soil” hypothesis, we previously sought to understand 
whether there were factors present in the lung that may interact with CD44+ breast cancer 
cells to promote lung metastasis, and observed that E-, L- and P-selectins, known ligands 
of CD44, were present in lung-conditioned media. In addition, previous animal studies that 
involved either breast cancer or colon cancer have demonstrated that deficiency or 
inhibition of each selectin independently significantly reduced the extent of lung 
metastasis. However, it is currently unclear whether E-, L-, and/or P-selectins specifically 
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derived from the lungs influence breast cancer cell metastatic behaviour, and if so, whether 
they do so through interactions with CD44.  
3 HYPOTHESIS 
Lung-derived selectins promote breast cancer migration and/or growth via 
interactions with CD44.   
4 SPECIFIC AIMS 
1. To determine the functional role of lung-derived selectins on breast cancer cell 
migration and/ or growth in vitro. 
2. To investigate the mechanism(s) by which lung-derived selectins influence breast 
cancer cell migration and/ or growth in vitro.   
5 MATERIALS & METHODS 
5.1 Cell Culture 
MDA-MB-231 (ATCC, Manassas, VA) human breast cancer cells were maintained 
in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) media 
(Invitrogen, Burlington, ON) + 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, 
MO). At 90% confluency, cells were passaged using 1 mM ethylene diamine tetraacetic 
acid (EDTA; Bioshop Canada Inc., Burlington, ON). SUM149 (Asterand Inc., Detroit, MI) 
were maintained in HAM’S F-12 media (Invitrogen) supplemented with 5% FBS (Sigma-
Aldrich), 5 𝜇g/mL insulin (Invitrogen), 1 𝜇g/mL hydrocortisone (Invitrogen) and 10 mM 
HEPES (Invitrogen). At 80% confluency, cells were passaged using 0.25% trypsin/EDTA 
in citrate saline (Life Technologies, Carlsbad, CA). Primary pulmonary mouse endothelial 
cells (generously provided by Dr. Sean Gill) were maintained in DMEM low 
glucose/pyruvate/L-Glutamine media (Thermo Fisher Scientific, Waltham, MA) 
supplemented with 18% heat-inactivated FBS (Sigma-Aldrich), penicillin-streptomycin 
(50 U/mL penicillin-50 𝜇g/mL streptomycin; Invitrogen) and HEPES (Invitrogen). Cells 
were cultured and maintained at 37°C and 5% CO2. 
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5.2 Lung-Conditioned Media 
5.2.1 Animal and Lung Harvesting 
Athymic nude mice were purchased and maintained under the guidelines of the 
Canadian Council of Animal care as outlined by the protocol approved by the University 
of Western Ontario Council on Animal Care (Appendix 1). Healthy 5-7 week old female 
athymic nude mice were euthanized by CO2 inhalation and their lungs and heart were 
aseptically removed en bloc. The heart was then carefully removed to avoid damaging the 
lungs and discarded, after which the lungs were placed in a pre-weighed 50 mL conical 
tube containing 30 mL of PBS. 
5.2.2 Lung-Conditioned Media Generation 
Following the harvesting of lungs (n=4 mice per session), the total weight of lungs 
+ PBS was determined using an electronic balance. Harvested lungs were washed three 
times in ice cold PBS before being minced into ~1 mm3 fragments. Lungs were weight-
normalized by re-suspension in a 4:1 media to tissue (v/w) ratio in DMEM:F12 
supplemented with Mito+ serum extender (1X; BD Biosciences, Mississauga, ON; basal 
media) and penicillin-streptomycin (50 U/mL penicillin-50 𝜇g/mL streptomycin; 
Invitrogen). Lung fragment/media suspensions were then incubated at 37°C and 5% CO2 
for 24 hours. Following incubation, conditioned media (CM) was further diluted four-fold 
in basal media, then separated from lung fragments by centrifugation at 900 g for 15 min 
at 4°C. Lung-CM was then filtered through a 0.22 𝜇m filter (Corning Inc., Corning, NY), 
aliquoted and stored at -80°C until use (Figure 3A). The original protocol for this model 
was described by Chu and colleagues21. 
5.2.3 Assessment of E-selectin, L-selectin and P-selectin Concentration 
To assess the presence and concentration of selectins in lung-CM, Quantikine® 
Mouse E-Selectin/CD26E, Quantikine® Mouse sP-selectin/CD62P, and Thermo Scientific 
Mouse L-selectin ELISA kits (R&D Systems, Minneapolis, MN, USA) were used. Basal 
media, lung-CM, and lung-CM depleted of E, L- or P-selectin (described below and in 




Figure 3. Lung conditioned media generation and selectin immunodepletion. (A) 
Healthy female nude mice were euthanized by CO2 inhalation and their lungs removed 
aseptically. Harvested lungs were then washed, minced into ~1 mm3 fragments, and 
resuspended in a 4:1 media to tissue (v/w) ratio for incubation at 37°C and 5% CO2 for 24 
h. Following incubation, heterogeneous solution is further diluted by three volumes of 
media, centrifuged and lung-CM filtered prior to use. (B) Immunodepletion of E-, P-, or 
L-selectin from lung-CM is accomplished using magnetic Protein-G Dynabeads®. I. An 
antibody specific to one type of selectin (E, P, L) bound to G-protein coupled Dynabeads® 
was added to lung-CM. II. Lung-CM/antibody-Dynabeads® mixture was mixed for 30 min 
to allow antibodies to bind their protein target present in lung-CM. III. After mixing, a 
magnet is used to separate lung-CM from the selectin antibody/Dynabeads® complexes. IV. 
The remaining lung-CM that is now depleted of the targeted protein is transferred to a 





out according to the manufacturer's instructions to measure the concentration of E-, L- and 
P-selectin in lung-CM and the efficiency of immunodepletion. A four-parameter logistic 
(4-PL) standard curve was generated for each experiment using GraphPad Prism 6.0 
(GraphPad Software, San Diego, CA) and used to determine the exact protein 
concentration in each sample. 
5.2.4 Selectin Immunodepletion from Lung-Conditioned Media 
To determine the influence of lung-derived selectins on in vitro migration and 
proliferation of breast cancer cells, E-, L- and P-selectin were individually immunodepleted 
from lung-CM using Dynabeads® Protein G (Life Technologies). Dynabeads were 
suspended in 200 𝜇L of wash buffer (PBS + 0.02% Tween-20) to equilibrate and then 
placed again on the magnetic rack for 2 min for separation from solution. Wash buffer was 
carefully removed and replaced with wash buffer + appropriate antibody. 
For E-selectin depletion, 20 𝜇L (0.6 𝜇g) of beads and 4 𝜇L of monoclonal E-selectin 
antibody (0.5 mg/mL; R&D Systems) were used per 1 mL of lung-CM. For L-selectin 
depletion, 10 𝜇L (0.3 𝜇g) of beads and 8 𝜇L of monoclonal L-selectin (0.5 mg/mL; R&D 
Systems) antibody were used per 1 ml of lung-CM. For P-selectin depletion, 30 𝜇L (0.9 
𝜇g) of beads and 50 𝜇L of polyclonal P-selectin antibody (0.2 mg/mL; R&D Systems) were 
used per 1 ml of lung-CM.  
The bead/antibody mixtures were first mixed by pipetting and then allowed to 
nutate for 20 min at RT. Following nutation, tubes were placed on the magnetic rack for 2 
min to separate antibody-bound beads from solution. The supernatant was carefully 
removed, and the antibody-bound beads were washed three times, before the beads were 
exposed to 1 mL of lung-CM. The antibody-bound bead and lung-CM mixture were then 
nutated for 30 min at RT. Post-nutation, samples were put on the magnetic rack for 2 min 
to separate the selectin/antibody/bead complexes from the now depleted lung-CM. A small 
aliquot of depleted lung-CM was stored for quantification of protein levels by ELISA and 
the rest was transferred to a new tube, passed through a 0.22 𝜇m syringe filter and stored 
at -80°C until use (Figure 3B). The selectin/antibody/bead complexes were washed in 
wash buffer and magnetically separated from solution three times. Selectin/antibody/bead 
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complexes were then suspended in 30 𝜇L of 1x Laemmli buffer and heated at 100℃ in a 
water bath for 5 min. Post-heating, samples were magnetically separated from beads, the 
supernatant was transferred to a clean tube and used for SDS-PAGE and immunoblotting. 
For rescue experiments, an amount of recombinant E-,L, or P-selectin protein that was 
equal to the calculated average concentration of each immunodepleted selectin was added 
back to depleted lung-CM (E-selectin [0.25 ng/mL], L-selectin [7.05 ng/mL]) and P-
selectin [10.39 ng/mL] (R&D Systems).  
5.3 Blood Collection and Lymphocyte Isolation 
Healthy 5-7-week-old female athymic nude mice were euthanized by CO2 
inhalation and blood was collected by ventricular puncture into heparin-containing tubes. 
Blood from four mice was combined and diluted 1:1 with PBS. Blood was layered over 15 
mL of Ficoll-Paque (Sigma-Aldrich) in a 50 mL conical tube and centrifuged at 500 x g 
for 30 min with the brake off. Immediately afterwards, a Pasteur pipette was used to 
carefully aspirate the mononuclear cell layer (located at the interface between the upper 
plasma and lower Ficoll-Paque layers) and transfer it to a new 50 mL conical tube. Ten mL 
of 0.8% ammonium chloride was mixed with the isolated cell layer to remove residual 
erythroid components. The sample was then centrifuged for 10 min at 400 x g. The 
supernatant was then decanted, and the cell pellet was resuspended in a small volume of 
cell lysis buffer (1% NP-40, 25mM Tris-HCl pH 7.5, 100 mM NaCl, 5% Glycerol, 1x 
Halt™ Protease Inhibitor Cocktail (Thermo Scientific)) for protein isolation.  
5.4 BrdU Incorporation Assay 
The bromodeoxyuridine (BrdU) incorporation assay was used to assess 
proliferation of MDA-MB-231 and SUM149 human breast cancer cells. Cells (1x104 
cells/well) were plated on 8-well Lab-tek™ chamber slides (Thermo Scientific) and 
incubated for 24 h to allow adhering. Cells were then washed once gently with PBS and 
serum starved for 72 h. Media was then changed to either basal media, positive control 
media (basal media + 10% FBS), lung-CM or E-, L- or P-selectin depleted lung-CM for an 
additional 24 h. Following incubation in the treatment conditions, cells were exposed to 
BrdU (5 μg/mL; Amersham Cell Proliferation Labelling Reagent; GE Healthcare, 
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Piscataway, NJ, USA) for 30 min to allow its incorporation into newly-synthesized DNA. 
Cells were washed with PBS and fixed with 10% neutral-buffered formalin (Fisher 
Scientific) for 5 min. Cell membranes were then permeabilized using 0.1% Triton X-100 
(Sigma) in PBS for 10 min and subsequently treated with 2N HCl (Fisher Scientific) for 
another 10 min to denature DNA. To minimize non-specific binding, slides were blocked 
for 30 min in 5% bovine serum albumin (BSA) in 0.1% Triton X-100 in PBS. For detection, 
anti-BrdU primary antibody (BD Biosciences) diluted 1:75 in 5% BSA/0.1% Triton X-100 
in PBS was added and slides were incubated overnight at 4℃. Unbound primary antibody 
was washed off with PBS and a FITC-conjugated anti-mouse IgG secondary antibody 
(H+L made in horse; Vector Laboratories, Burlington, ON, Canada) diluted 1:100 in 5% 
BSA + 0.1% Triton X-100 in PBS was added for 1 h at RT. Unbound secondary antibody 
was washed off using PBS and the slides were then mounted with ProLong Gold Antifade 
Mountant with DAPI (Invitrogen) and allowed to cure overnight in the dark at RT. Five 
high powered fields of view (FOV) were taken per well and nuclei enumerated using 
ImageJ. Results were expressed as the percentage of BrdU positive cells to total nuclei. 
5.5 Transwell Migration Assay 
The migration of MDA-MB-231 and SUM149 human breast cancer cells towards 
lung-CM was assessed using transwell migration assays. Prior to the start of the assay, 
Fluoroblok™ transwell inserts (24-well, 6.4 mm polyethylene terephthalate membrane, 8 
𝜇m pore size; Corning Inc., Corning, NY, USA) were coated with 100 𝜇L of gelatin (6 
𝜇g/well; Bioshop) and allowed to dry overnight in a sterile environment at RT. 
Immediately prior to the assay, the gelatin was reconstituted with 100 𝜇L of control media 
(DMEM:F12 + Mito+ + 0.1% BSA; Bioshop) and agitated for 90 min at RT. During the 
reconstitution incubation, MDA-MB-231 or SUM149 cells were harvested, washed twice 
with PBS and suspended at a concentration of 5 x 105 cells/mL. After reconstitution, excess 
media from the top of the transwells was carefully removed and 100 𝜇L of cell suspension 
was added in replacement. In the lower compartment of the transwell chamber, 600 𝜇L of 
either negative basal media, 1:2 diluted lung-CM or 1:2 diluted lung-CM depleted of E-, 
L- or P-selectin was added. Transwells were then incubated for 18 hours at 37°C and 5% 
CO2 to allow migration. After 18 hours, transwell chambers were removed, fixed with 1% 
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glutaraldehyde in PBS (Fisher Scientific) for 20 min. Transwell membranes were then 
washed once with distilled water and a cotton swab was used to remove the non-migrated 
cells from the inner portion of the membrane. Membranes were then carefully cut out, 
placed on microscope slides and mounted using ProLong® Gold Antifade Mountant with 
DAPI (Life Technologies). Five high powered FOV were captured for each membrane, 
and a mean number of migrated cells/FOV was calculated using ImageJ software (NIH, 
Bethesda, MD, USA).  
5.6 Co-immunoprecipitation 
To assess potential interactions between selectins and CD44, co-
immunoprecipitation was performed. Confluent 100 mm dishes of MDA-MB-231 cells 
were washed three times with PBS and lysed with 500 𝜇L of lysis buffer (1% NP-40, 25mM 
Tris-HCl pH 7.5, 100 mM NaCl, 5% Glycerol, 1x Halt™ Protease Inhibitor Cocktail 
[Thermo Scientific]). Lysates were collected using cell scrapers and transferred to a 1.5 
mL microfuge tube that was then placed on ice for 1 h. Following the incubation period, 
lysates were centrifuged for 10 min at 13,000 g and 4℃. During this period, 20 𝜇L (0.6 𝜇g) 
of Dynabeads were equilibrated in 200 𝜇L of wash buffer (25mM Tris-HCl pH 7.5, 100 
mM NaCl, 5% Glycerol) and placed on a magnetic rack for 2 min to separate from solution. 
Wash buffer was carefully removed and replaced with 500 𝜇L of MDA-MB-231 cell lysate 
supernatant. The remaining pellet from the cell lysates was discarded.  
Two micrograms of recombinant mouse E-selectin Fc chimera protein, 
recombinant mouse L-selectin Fc chimera protein or recombinant mouse P-selectin Fc 
chimera protein (R&D Systems) was added to each tube containing cell lysate/beads. Cell 
lysate/beads without recombinant protein was used as a negative control. 
Lysate/bead/recombinant protein mixtures were placed on a rotator overnight at 4℃. The 
following morning, tubes were placed on a magnetic rack to separate beads/bound proteins 
from solution. The supernatant was then carefully removed, and remaining beads were 
resuspended in wash buffer, washed and magnetically separated. The wash and separation 
steps were repeated twice, beads were suspended in 30 𝜇L of Laemmli buffer, and boiled 
for 5 min in a 100 ℃ water bath. After boiling, samples were placed on the magnetic rack 
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for 2 min and the supernatant was transferred to a clean 1.5 ml microfuge tube for storage 
at -20℃ until SDS-PAGE and immunoblotting were performed. 
5.7 Immunoblotting 
Cell lysates were quantified using the DC Protein Assay (Biorad, Hercules, CA). 
Thirty micrograms of cell lysates or 30 𝜇L of immunoprecipitated samples were subjected 
to separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and transferred onto polyvinylidene difluoride membranes (PVDF; Millipore, Billerica, 
MA). Membranes were blocked using 5% skim milk in Tris-buffered saline + 0.1% Tween-
20 (TBS-T; Sigma) for all western blots, unless otherwise indicated. Primary and 
secondary antibody concentrations used are described in Table 2. Protein expression was 
visualized using Clarity Max™ Western ECL Substrate (Bio-Rad) and normalized by 
immunostaining for beta-actin as a loading control. 
5.8 Phosphokinase Array 
MDA-MB-231 human breast cancer cells were serum starved for 24 h and then 
exposed to one of three conditions for 15 min: basal media, lung-CM or lung-CM depleted 
of L-selectin. Immediately after treatment, cells were gently washed three times with cold 
1x PBS and lysed with lysis buffer. Lysates protein concentrations were measured using 
the BioRad DC protein assay (BioRad). The phospho-kinase array (Proteome Profiler™ 
Human Phospho-Kinase Array; R&D Systems) was carried out using 200 µg of each lysate 
as per the manufacturer's guidelines. Using the kit-provided wash buffer, unbound proteins 
were removed from membranes, and a cocktail of detection antibodies was applied. To 
detect the amount of phosphorylated protein bound to each capture spot, streptavidin-HRP 
and chemiluminescent agents were used to produce a signal. The signals were then 
visualized using a ChemiDoc System and analyzed for densitometry using Image Lab™ 
Software (BioRad) (n=3 for each treatment condition). To validate the accuracy of the 
phospho-kinase array and expand the number of treatment conditions being examined with 
respect to identified proteins of interest, immunoblotting was performed. MDA-MB-231 




Table 2. Details of primary and secondary antibodies used for immunoblotting  










1° Human 𝛽-actin Polyclonal Sigma Rabbit 
1:5000 
O/N at 4℃ 
 
1° Human CD44S 156-3C11 Invitrogen Mouse 
1:100 
O/N at 4℃ 
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O/N at 4℃ 
2° Goat Goat IgG Polyclonal Calbiochem Rabbit 
1:2000 
(1 h @ RT) 
2° Mouse Mouse IgG Polyclonal Calbiochem Goat 
1:2000 
(1 h @ RT) 
2° Rabbit Rabbit IgG Polyclonal Calbiochem Goat 
1:2000 
(1 h @ RT) 
2° Rat Rat IgG Polyclonal Calbiochem Goat 
1:2000 





recombinant protein (individual selectins diluted in basal media) conditions for 15 min as 
described earlier and analyzed by immunoblotting for specific proteins of interest. 
5.9 Statistical Analysis 
A minimum of three biological replicates were performed for each experiment, with 
three technical replicates within each experiment for transwell migration and BrdU 
incorporation assays. All statistical analyses were performed using GraphPad Prism 6.0 
(San Diego, CA, USA), and data are presented as mean ± standard error of the mean (SEM). 
A one-way analysis of variance (ANOVA) was used to compare means between treatment 
groups, followed by a Tukey’s post-hoc test to confirm significance. In some cases, a 






6.1 E-, L-, and P-selectin are present in lung-CM 
We have previously demonstrated that lung-CM generated from the lungs of 
healthy female mice can be used as a model of the soluble lung microenvironment. Using 
protein array analysis, we identified over 70 lung-derived proteins in lung-CM that are not 
present in basal media25. In particular, E-, L- and P selectin were identified as proteins for 
further investigation based on their previous association with metastasis and the fact that 
they were known CD44 ligands88-90. Using ELISA, the presence and concentration of each 
selectin protein was quantified in lung-CM relative to basal media. We observed that E-
selectin (Figure 4A), L-selectin (Figure 4B) and P-selectin (Figure 4C) are present in 
lung-CM at significantly higher concentrations than in basal media (p<0.05). Each selectin 
could be successfully individually immunodepleted, resulting in lung-CM that had 
significantly reduced levels of E-, L, or P-selectin compared to non-depleted lung-CM 
(p<0.05). In the absence of a specific antibody, Dynabeads® Protein G alone had no 
significant effect on immunodepletion of selectins. Analysis of positive controls (activated 
endothelial cells) demonstrated the specificity of the ELISA for the selectins of interest. 
We were also interested in trying to determine which selectin forms 
(cleaved/soluble versus full-length) were present in lung-CM and attempted to characterize 
this by immunoblot analysis of the immunoprecipitated fractions (Appendix 2). However, 
lack of optimal antibodies for immunoblotting and the small difference in molecular weight 
and antibody specificity made it very difficult to resolve two close bands in the case where 
both forms might be potentially present, or to identify a band as one form with certainty 
(in humans, it has been reported that the soluble forms of each selectin are 3-6 kDa smaller 
than their full-length counterparts, as they are cleaved at a membrane proximal region such 




Figure 4. E-, L-, and P-selectin are present in lung-conditioned media (CM) and can 
be immunodepleted. Lung-CM generated from the lungs of healthy female nude mice was 
assessed for the presence and concentration of (A) E-selectin, (B) L-selectin, and (C) P-
selectin protein by ELISA, and immunodepletion (denoted by  symbol) was carried out 
using specific respective antibodies coupled to Dynabeads® Protein G. Immunodepletion 
controls included basal media, lung-CM exposed to Dynabeads Protein G only, and lung-
CM exposed to Dynabeads plus a nonspecific anti-mouse IgG antibody. Lysates of 
lipopolysaccharide-stimulated mouse endothelial cells (EC) were used as an additional 
positive control for E- and P-selectin. Data is presented as mean protein concentration +/- 
SEM. (n=3). Analysis was carried out using a one-way ANOVA and Tukey’s post hoc test. 
* = significantly different than basal media (p<0.05); # = significantly different than 




6.2 Lung-derived selectins enhance breast cancer cell migration 
 Recent findings from our lab have demonstrated that cell migration of several breast 
cancer cell lines including MDA-MB-231 and SUM149 is increased in response to lung-
CM relative to basal media25. To determine whether this effect is due in part to the presence 
of E-selectin, L-selectin and/or P-selectin in lung-CM, a transwell migration assay was 
used. MDA-MB-231 (Figure 5A) or SUM149 (Figure 5B) human breast cancer cells were 
exposed to one of the following conditions for 18 hours: basal media, lung-CM, or lung-
CM depleted of E-selectin, L-selectin or P-selectin. Relative to the negative control basal 
media, MDA-MB-231 and SUM149 human breast cancer cells demonstrated significantly 
higher migration towards lung-CM (p<0.05). This increased migration towards lung-CM 
could be abrogated in both cell lines when each selectin was individually immunodepleted 
(p<0.05). Addition of specific recombinant mouse selectins to depleted lung-CM at a level 
that restored selectin protein levels to those detected in the naive lung-CM rescued the pro-
migratory effect of lung-CM to levels consistent with the non-depleted lung-CM (p>0.05). 
Taken together, these results indicate that lung-derived E-, L-, and P-selectins can enhance 
breast cancer cell migration. 
6.3 Breast cancer cell proliferation is independent of lung-
derived selectins 
Our group has also previously observed that lung-CM can not only increase 
migration, but also influences the proliferation of human breast cancer cells25. To 
determine whether selectins are contributing to the observed proliferative effect of lung-
CM, BrdU incorporation assays were used. MDA-MB-231 and SUM149 human breast 
cancer cells were exposed to basal media, lung-CM, or lung-CM depleted of E-selectin, L-
selectin or P-selectin for 24 h. Cells were then transiently exposed to BrdU and 
incorporation was detected by immunofluorescence. Consistent with our previous study25, 
we observed that a greater proportion of MDA-MB-231 (Figure 6A,B) and SUM149 cells 
(Figure 6C,D) were BrdU-positive following exposure to lung-CM relative to basal media 







Figure 5. Lung-derived selectins enhance breast cancer cell migration. (A) MDA-MB-
231 or (B) SUM149 human breast cancer cells (5 x 10
4
 per well) were plated in triplicate 
(n= 3) on top of gelatin-coated Corning® Fluroblok™ transwells (8-µm pore size) before 
exposure to one of the following conditions: basal media; lung-CM; lung-CM depleted of 
E-selectin; L-selectin or P-selectin (denoted by  symbol); or depleted lung-CM + 
recombinant E-selectin, L-selectin or P-selectin (added at the concentration needed to 
restore protein levels to that observed in native lung-CM). Cells were allowed to migrate 
for 18 hours at 37°C and 5% CO2. Transwells were fixed, stained with DAPI, and five high-
powered images were captured per transwell. Migrated cells were analyzed using ImageJ 
software (NIH). Data is presented as mean fold-change in number of migrated cells relative 
to basal media +/- SEM (n=3). Analysis was done with one-way ANOVA and Tukey’s post 
hoc test. * = significantly different from basal media (p<0.05); # = significantly different 




Figure 6. Breast cancer cell proliferation is independent of lung-derived selectins. 
(A,B) MDA-MB-231 and (C,D) SUM149 human breast cancer cells were plated at a 
density of 1x104 cells/well on 8-well chamber slides and serum starved for 72 hrs. Cells 
were then exposed to basal media, lung-CM, and lung-CM depleted of E-selectin, P-
selectin or L-selectin (denoted by  symbol) for an additional 24 h before assessing 
proliferation based BrdU incorporation. Five high-powered images per well were captured 
and used to enumerate the percentage of BrdU-positive cells using ImageJ software (NIH). 
Data is presented as mean fold-change in BrdU relative to basal media +/- SEM (n=3). *= 




depletion of E-selectin, L-selectin and P-selectin from lung-CM (p>0.05), suggesting that 
breast cancer cell proliferation is independent of lung-derived selectins. 
6.4 Mouse selectins interact with human CD44 expressed by 
MDA-MB-231 cells 
 To  assess whether CD44S expressed by human breast cancer cells could interact 
with murine selectins, we performed co-immunoprecipitation. The three selectin proteins 
used were the soluble forms of mouse E-selectin-human IgG1 chimeric protein, mouse L-
selectin-human IgG1 chimeric protein and mouse P-selectin-human IgG1 chimeric proteins 
(R&D Systems). Since all three proteins contained a fused IgG region, it was theoretically 
possible for them to interact directly with Dynabead® Protein G. We confirmed this by 
incubating Dynabead® Protein G alone or in combination with one of the selectin proteins 
overnight at 4℃. Samples were immunoprecipitated and analyzed by immunoblotting 
(Figure 7) for the respective selectin protein using antibodies and conditions described in 
Table 2. 
A single band was observed in each lane containing recombinant protein that 
immunoprecipitated with the Dynabead® Protein G (Figure 7A). This suggested that the 
recombinant chimeric selectins could interact directly with the Dynabead® Protein G 
without additional antibodies. We then went on to test whether CD44S interacted with the 
murine selectin proteins. Cell lysates from MDA-MB-231 human breast cancer cells were 
incubated overnight at 4℃ with Dynabead® Protein G alone or in combination with one of 
the murine selectin-human IgG1 chimeric proteins. Immunoprecipitates were then assessed 
by immunoblotting for human CD44S using antibodies and conditions described in Table 
2. Bands corresponding to proteins of approximately 90 kDa in weight reacted with the 
CD44S antibody and were observed in each of E-, L- and P-selectin immunoprecipitates 
(Figure 7B). The protein size detected was consistent with the band observed from the 
MDA-MB- 231 cell lysate input control. This suggests that murine E-, L-, and P-selectin 





Figure 7. Mouse selectins interact with human CD44S expressed by MDA-MB-231 
cells. A) Dynabead® Protein G were incubated alone or with a murine E-, L- or P-selectin-
human IgG1 chimeric protein (R&D Systems) overnight at 4℃. Proteins potentially bound 
to Dynabead® Protein G were isolated and analyzed by immunoblotting. Membranes were 
blocked with 5% BSA in TTBS for 1 h at room temperature before overnight incubation at 
4℃ with an anti-E-selectin (1:500), anti-L-selectin (1:1000) or anti-P-selectin (1:1000) 
antibody diluted in 5% BSA in TTBS. Membranes were then washed with PBS and 
incubated at room temperature for 1 h with an anti-rat IgG, anti-rat IgG or anti-goat IgG 
secondary antibody (all diluted 1:2000 in 5% BSA in TTBS) for E-, L- and P-selectin, 
respectively. Membranes were visualized by chemiluminescence and captured on a 
ChemiDoc™ Imaging Systems. (n=3). B) MDA-MB-231 cell lysates were incubated 
overnight at 4℃ with Dynabeads® Protein G alone or with 2𝝁g of murine E-, L- or P-
selectin-human IgG1 chimeric protein. Immunoprecipitates were isolated and 
immunoblotted. Membranes were blocked with 5% BSA in TTBS for 1 h at room 
temperature, then incubated overnight at 4℃ with an anti-CD44S antibody (1:100 diluted 
in 5% BSA in TTBS) and incubated at room temperature for 1 h with an anti-mouse IgG 
secondary antibody (1:2000 dilution in 5% BSA in TTBS) the following morning. 
Membranes were then visualized by chemiluminescence and captured on a ChemiDoc™ 
Imaging Systems. (n=3). 
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6.5 Effect of lung-derived selectins and CD44 on migration-
related signaling pathways 
 To determine whether the interaction between selectins and CD44S contributes to 
the pro-migratory effect of selectins that we observed in our earlier experiments, 
immunoblotting was used to investigate the effect of lung-derived selectins and/or CD44 
on migration-related signaling pathways. The highly related ERM (ezrin, radixin, moesin) 
proteins were of interest in examining because when phosphorylated they have been shown 
to serve as linkers between CD44 receptors and the cytoskeleton91, 92. Through this role, 
ERM proteins may facilitate pro-migratory signals93. Serum-starved MDA-MB-231 cells 
were exposed for 15 min to native lung-CM or lung-CM that was depleted of E-, L- or P-
selectin. Cellular response to lung-CM in the presence of a functional blocking antibody 
against CD44S was also assessed. Cell lysates were collected and assessed by 
immunoblotting for total ERM and phosphorylated ERM proteins (Figure 8). No 
statistically significant changes in the ratio of ERM phosphorylation were observed among 
treatments when examined together by one-way ANOVA. However, a direct comparison 
of basal media and lung-CM treatments by t-test demonstrated that phosphorylation was 
significantly increased in response to lung-CM (p<0.05). Taken together, this data suggests 
that ERM phosphorylation is increased by proteins found in lung-CM but the effect is 
independent of lung-derived selectins.  
 Given the complexity of intracellular signalling pathways and how they may mediate 
migration and/ or proliferation, we used the Proteome Profiler™ Human Phospho-Kinase 
Array (R&D Systems) to determine what additional proteins may be involved. This array 
simultaneously profiles changes in the phosphorylation of 43 protein kinases and two 
related total proteins. Lysates examined were from MDA-MB-231 cells that were treated 
for 15 min with either basal media, lung-CM or lung-CM depleted of L-selectin. Relative 
to the basal media treatment, the phosphorylation of a few proteins was significantly 
increased by lung-CM treatment (Figure 9) (p<0.05). These proteins included extracellular 
signal-regulated kinase 1 and 2 (ERK1/2), mitogen- and stress-activated protein kinases 1 
and 2 (MSK1/2), cAMP response element binding protein (CREB) and tyrosine-protein 




Figure 8. Effect of lung-conditioned media on ERM protein phosphorylation in 
human breast cancer cells. MDA-MB-231 cells were cultured to 90% confluence and 
then serum starved for 24 h. Cells were then exposed for 15 min to one of the following 
conditions: basal media, lung CM, or lung CM depleted of E-selectin, P-selectin, L-selectin 
(denoted by  symbol). Cellular response to lung-CM in the presence of a functional 
blocking antibody against CD44S (CD44) was also assessed. Cells were lysed, protein 
was quantified by Lowry assay and analyzed by immunoblotting. Membranes were 
blocked with 5% BSA in TTBS for 1 h at room temperature before immunostaining 
overnight at 4℃ with the primary antibody for ERM (1:1000 diluted in 5% BSA in TTBS) 
or phosphorylated ERM (1:1000 diluted in 5% BSA in TTBS). The region of the membrane 
at the molecular weight of actin was cut and probed with an anti-actin antibody (1:5000 
diluted in 5% BSA in TTBS.) The following day, membranes were washed with PBS and 
incubated with anti-rabbit secondary antibody (1:2000) for 1 hour at room temperature. 
Bands were visualized using enhanced chemiluminence (ECL) and captured on a 
ChemiDoc™ Imaging Systems. Quantification was carried out by densitometry using 
ImageLab software. Data is presented as fold-change in ratio of total:phosphorylated ERM 





Figure 9. Effect of lung conditioned media on protein phosphorylation in breast 
cancer cells. MDA-MB-231 human breast cancer cells were incubated in basal media, 
lung-CM or lung-CM depleted of L-selectin () for 15 minutes. Cells were then collected, 
lysed and incubated with the Human Phospho-Kinase Array membrane (R&D systems) as 
per the manufacturer’s instructions. The presence of phosphorylated proteins was detected 
using biotinylated antibodies and visualized by chemiluminescence. A) Representative 
arrays of the basal media, lung-CM and lung-CM depleted of L-selectin are presented. 
Boxes outlined with dashed lines indicate internal positive controls. Boxes outlined with a 
solid line are proteins of interest. Extracellular signal-regulated kinase 1 and 2 (ERK1/2), 
mitogen- and stress-activated protein kinase 1 and 2 (MSK1/2), cAMP response element-
binding protein (CREB) and tyrosine-protein kinase Lyn are numbered 1 to 4, respectively. 
B) Densitometry analysis was performed using Image Lab software (Bio-Rad) and one-
way ANOVA with Tukey’s post-hoc statistical analysis was performed using GraphPad 
Prism software. * = significantly different from basal media (p<0.05); # = significantly 
different from lung-CM (p<0.05). Only kinases/proteins with significantly different 







to non-depleted lung-CM (p<0.05) was only observed for the kinase LYN, although a non-
significant trend (p>0.05) was also observed for CREB. Although the LYN effect could 
not be validated by immunoblotting (data not shown), CREB was analyzed in greater detail 
to determine whether lung-derived selectins might signal through this pathway. MDA-MB-
231 cells were exposed to non-depleted lung-CM or that which had been depleted of E-, 
L-, or P-selectin. Cellular response to lung-CM in the presence of a functional blocking 
antibody against CD44S was also assessed. Cell lysates were analyzed by immunoblotting 
for total and phosphorylated CREB. We observed that while lung-CM treatment 
significantly increased CREB protein phosphorylation relative to basal media (p<0.05) 
(consistent with phosphokinase array results), immunodepletion of single selectins or 
blocking with CD44 did not significantly affect CREB phosphorylation (p>0.05), although 
a non-significant trend could be seen whereby CREB phosphorylation appears to be lower 
in cells exposed to selectin-depleted lung-CM compared to native lung-CM, or cells 
blocked by CD44 (Figure 10A). In an alternative approach, when MDA-MB-231 cells 
were treated with recombinant E-, L- and P-selectin at concentrations 10x higher than those 
observed in lung-CM, a slight but non-significant increase in CREB phosphorylation 









Figure 10. Lung-conditioned media enhances CREB phosphorylation. MDA-MB-231 
cells were cultured to confluence and subjected to serum starvation for 24 hours. Following 
this period, cells were exposed to treatment conditions for 15 min and then harvested, lysed 
and their protein concentrations quantified by BioRad DC Protein Assay. 30 ug of protein 
from each lysate was analyzed by immunoblotting. Membranes were blocked for 1 h at 
room temperature with 5% milk in TTBS, followed by incubation with either P-CREB 
(1:1000 dilution in 5% milk in TTBS) or CREB (1:1000 in 5% milk in TTBS) primary 
antibody overnight at 4℃. The following morning, membranes were washed with TTBS 
and then incubated with an anti-rabbit IgG secondary antibody for 1 hour before 
visualization by chemiluminescence. Images were captured on a BioRad ChemiDoc 
system and quantified by densitometry using ImageLab® software. One-way ANOVA and 
Tukey’s post-hoc test were performed using GraphPad Prism software, and results are 
presented as mean ± SEM (n=3) (A) Cells were treated with basal media, lung-conditioned 
media (lung-CM) or lung-CM depleted of L-selectin, E-selectin, P-selectin. Cellular 
response to lung-CM in the presence of a functional blocking antibody against CD44S 
(CD44) was also assessed. (B) Cells were treated with basal media, lung-CM or 
recombinant protein in basal media (mouse E-, L- or P-selectin) at concentrations ten-fold 






Breast cancer is the most commonly diagnosed cancer (with the exception of non-
melanoma skin cancers) and second leading cause of cancer-related deaths among 
Canadian women94. Since the 1970s, considerable progress has been made in the clinical 
management of the disease, with five-year survival rates having risen from 53% in the 
1970s to almost 87% for women in 201695. This improvement can be primarily attributed 
to improved early detection and the development of therapies that target the estrogen 
receptor (e.g. tamoxifen) and the HER2 receptor (trastuzumab)96-98. Unfortunately, triple-
negative breast cancer, the most aggressive subtype, does not express ER or HER2 
receptors and no other effective targeted therapy exists99. In the metastatic setting, breast 
cancer currently remains incurable.  
The "seed and soil" hypothesis was originally proposed by Stephen Paget in 1889 
and postulated that the formation of metastatic tumours at distant sites was related to not 
only the intrinsic properties of the breast cancer cell (the “seed”) but also to factors found 
in the organ microenvironment (the “soil”) that would allow the tumour cell to survive and 
grow24. For three of the most common sites of breast cancer metastasis (lung, brain and 
bone), studies conducted by Joan Massagué and colleagues elegantly demonstrated how 
the genetic signature of breast cancer cells can contribute to determining organ-specific 
metastasis26-28.  
To study the influence of organ microenvironments common to breast cancer 
metastasis, our group previously developed an ex vivo model that allowed the soluble 
factors produced by a given tissue to be identified and their influence examined25. With 
respect to the lung, we found that at least 70 unique soluble proteins are present, and that 
these proteins include chemokines, cytokines, growth factors and extracellular matrix 
components. Five of the identified proteins are known interactors of CD44, an extracellular 
receptor that is a marker for aggressive breast cancer cells34. These proteins include basic 
fibroblast growth factor100, osteopontin51, E-53, L-54 and P-selectin88. Our group has 
demonstrated that basic fibroblast growth factor promotes the proliferation of breast cancer 
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cells101, L-selectin promotes the migration of breast cancer cells and OPN enhances both 
metastatic behaviours in vitro25.  
This thesis focused on investigating the role and potential mechanisms of lung-
derived E-, L, and P-selectin in breast cancer metastatic behavior. We hypothesized that 
lung-derived selectins promote breast cancer migration and/or growth via interactions with 
CD44. 
7.1 Summary of Experimental Findings 
1. E-selectin, L-selectin and P-selectin are present in significant concentrations in lung-
CM and can be immunodepleted.  
2. Each of the three selectin proteins promotes the in vitro migration of MDA-MB-231 
and SUM-149 human breast cancer cells towards lung-CM.  
3. Lung-CM promotes the in vitro proliferation of MDA-MB-231 and SUM-149 breast 
cancer cells but its effect is independent of selectins.  
4. CD44S expressed by MDA-MB-231 human breast cancer cells in vitro interacts with 
soluble mouse E-, L- and P-selectin. 
5. The phosphorylation of ezrin/radixin/moesin (ERM) proteins in MDA-MB-231 
breast cancer cells is enhanced by exposure to lung-CM but is not significantly 
affected by depletion of individual selectins. 
6. Phosphorylation of CREB in MDA-MB-231 cells is significantly increased following 
exposure to lung-CM relative to a basal media control but is not significantly 
influenced by selectin depletion or addition.  
7.2 Implications of Experimental Findings 
The findings of this project support the hypothesis that lung-derived selectins have a 
pro-metastatic role in breast cancer, specifically through migration. Our group was the first 




7.2.1 Forms of Selectins Found in Lung-Conditioned Media 
In the literature, the in vivo presence and expression of selectins in the lung has been 
well-established25, 102, 103. Using ELISA, we quantified the amount of each selectin in lung-
conditioned media. While we cannot confirm whether the concentrations observed are 
equal to those observed in the native lung microenvironment, we can at least appreciate 
their presence, the relative amounts of each selectin family member, and begin to 
understand the role they may have in breast cancer metastatic behavior. 
Due to the nature of our lung-CM model and the need for mechanical dissociation of 
mouse lungs, the possibility exists that some of each selectin detected by ELISA was of 
the full-length form. Full-length forms of the protein could have been released from the 
cell membrane if mechanical dissociation of the lungs damaged the cells. We attempted to 
determine the presence and relative amount of full-length versus soluble forms of each 
selectin by immunoprecipitation and subsequent immunoblotting. In humans, the soluble 
form of each selectin is approximately 3-6 kDa smaller that its full-length counterpart, and 
the soluble forms of the protein are generated by cleavage at a membrane proximal site 
such that the transmembrane and cytoplasmic regions are removed68-70.  Unfortunately, a 
lack of optimal antibodies and the small difference in molecular weights between the two 
forms of each selectin made it difficult to resolve and identify which species were present 
in our lung-CM. However, studies suggest that both soluble and full-length forms of each 
protein (E-selectin104, 105, L-selectin73 and P-selectin106) interact with the same 
receptors/binding partners. Therefore, both forms should theoretically exert the same 
functional influence on breast cancer cells in our ex vivo model.  
7.2.2 Lung-derived Selectins are Important for Breast Cancer Migration 
but not Growth 
Next we assessed the functional influence of lung-derived selectins on breast cancer 
cells and whether it occurs through CD44S, a cell surface receptor that has a well-
characterized role in regulating the proliferation, migration and invasion of breast cancer 
cells107. Selectins present in lung-CM were observed to play significant roles in migration 
of breast cancer cells but did not influence proliferation, as assessed by transwell migration 
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and BrdU incorporation assays, respectively. A study conducted by Kumar and colleagues 
was among the first to demonstrate that soluble E-selectin had a chemotactic effect on 
immune cells72. This was followed by a recently published study in which soluble E-
selectin was shown to promote the migration of MDA-MB-231 human breast cancer cells 
potentially through interactions with CD44108, which supports our findings. With respect 
to proliferation, there is no direct evidence implicating E-selectin in the proliferation of 
cancer cells in vitro. However, soluble E-selectin has previously been shown to mediate 
angiogenesis in vitro and in the context of breast cancer, E-selectin deficiency has reduced 
the number of lung metastatic foci86. It is difficult to extrapolate whether changes in the 
number of metastatic foci observed were related to migration and/or proliferation, as no 
comparison in the size of metastatic foci was made between wild-type and E-selectin 
deficient mice.   
In comparison to E-selectin, relatively little is known about L-selectin and its influence 
in breast cancer. In the context of breast cancer, previous work by our laboratory 
demonstrated that the migration of MDA-MB-231 human breast cancer cells towards lung-
CM was mediated in part by L-selectin25. The work of this thesis added to our previous 
findings by demonstrating that the migration of MDA-MB-231 breast cancer cells 
abrogated by depletion of L-selectin from lung-CM could be rescued through addition of 
recombinant L-selectin, and by replicating these experiments with all three selectins and in 
a second breast cancer cell line, SUM149. 
There are many studies that have used animal models of cancer to examine the role of 
P-selectin in metastasis. One of these used a spontaneous model of breast cancer metastasis 
and interestingly observed that although P-selectin deficiency in mice did not decrease the 
incidence of lung metastasis, the overall metastatic burden in the lung was significantly 
higher than that of their wild-type counterparts86. They suggested an impaired ability of P-
selectin deficient mice in recruiting neutrophils and monocytes was driving this 
observation109. However, in other cancers, such as melanoma and colon carcinoma, 
opposing results were observed. In an experimental model of melanoma metastasis in 
which cancer cells were intravenously administered into mice, the number of lung 
metastases in P-selectin deficient mice was less than half of that observed in wild-type 
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mice110. Similarly, in a spontaneous metastasis model of colon carcinoma, only 11% of P-
selectin deficient mice had any histological signs of tumour cells or microscopic nodules 
in the lungs. In comparison, signs of metastasis were observed in 89% of wild-type mice 
injected with tumour cells103.  
At the cellular level, published evidence has suggested a role for P-selectin in cancer 
cell proliferation, with subcutaneously implanted colon carcinoma cells having 
significantly lower primary tumour growth in P-selectin deficient mice versus in wild-
type103.  To the best of our knowledge, no previous studies have investigated the influence 
of P-selectin (lung-derived or otherwise) on migration or proliferation in the context of 
breast cancer, although a previous study by Morbidelli and colleagues demonstrated that 
soluble P-selectin could promote endothelial cell migration in vitro111.  
While we did not explore the effects of depleting multiple selectins from lung-CM, we 
did observe that depletion of each selectin individually significantly affected migration of 
breast cancer cells. It is possible that the selectins may either function through interactions 
with different receptors at the cell surface or by activating different intracellular 
mechanisms. This idea is supported by a study on lung metastasis of adenocarcinoma in 
mice. Borsig and colleagues observed that mice deficient in P-selectin and L-selectin had 
a significantly lower burden of lung metastasis than wild-type mice or those deficient in 
only one of the selectins (L- or P-selectin)87. How selectins function in the context of 
metastasis, whether it is through a single receptor or mutual downstream mechanisms, has 
not been well examined. Furthermore, it is still not clear whether each selectin functions 
differently/synergistically in migration of breast cancer cells, and/or whether E-,L- and P-
selectin may be redundant/compensatory for each other. 
7.2.3 Interaction of Lung-Derived Selectins with CD44 
The receptor that we were most interested in examining was CD44, as previous 
evidence has not only supported a role for the receptor in cell migration/invasion57, but also 
demonstrated that it can interact with all three selectins53-55. An interaction of E-selectin 
with CD44 expressed by LS174T colon carcinoma cells was originally hypothesized based 
on CD44 immunoreactivity with the HECA-452 antibody, which detects sialofucosylated 
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oligosaccharides (a group that E-selectin binds to)112. For P- and L-selectin, studies 
demonstrated an interaction with CD44 by blot rolling assays88. However, detection of a 
direct interaction by co-immunoprecipitation of selectins with CD44 expressed by breast 
cancer cells has only been reported for E-selectin113. We therefore investigated this further 
using recombinant mouse soluble selectin-human IgG chimera proteins, which are capable 
of directly interacting with Dynabead® Protein G. This allowed us to avoid potential issues 
of immunoprecipitating CD44 or selectins using antibodies that target the ectodomains 
through which they may interact, since the IgG region that interacts with the Dynabead® 
Protein G is located near the C-terminus of the chimera, far from the ectodomains. We 
tested this using soluble mouse selectins, as these were the forms that we hypothesized 
were found in our lung-CM model.  
The interaction of CD44 with mouse selectins that we observed was facilitated by the 
high degree of homology shared between human and mouse selectins. There is on average, 
72% homology in the lectin region of selectins between mouse and human63. Whether 
and/or how this interaction might activate CD44-associated pro-migratory signaling 
pathways was examined in further studies. 
7.2.4 Potential Mechanisms Underlying the Pro-Migratory Effect of 
Lung-Derived Selectins 
Previous studies have suggested ERM (ezrin/radixin/moesin) proteins are involved in 
promoting migration, potentially through their roles as crosslinkers between CD44 and the 
underlying actin cytoskeleton114, 115. For example, the N-terminal domain of 
phosphorylated ezrin binds to the cytoplasmic tail of CD44 and the C-terminal domain of 
ezrin binds to actin. This function is only possible when the ERM proteins are 
phosphorylated at key threonine residues91. In their respective unphosphorylated states, the 
N- and C-terminal domains of ERM proteins self-associate and make the protein 
conformationally inaccessible to binding partners116. Based on these previous studies, we 




In our results, we observed that exposure of human breast cancer cells to lung-CM 
increased ERM phosphorylation relative to the basal media negative control. However, no 
significant differences in phosphorylation were observed between control, lung-CM, lung-
CM depleted of a single selectin type or when cells were pre-treated with a neutralizing 
antibody for CD44. This suggested that the effect of selectins on CD44-associated 
migration may not be through induced changes in ERM phosphorylation. Rather, selectin 
interactions with CD44 may affect CD44-pERM interaction. A recent study by Donatello 
and colleagues observed that there were no differences in the ratio of phosphorylated to 
total ERM proteins between migrating and non-migrating breast cancer cells117. However, 
by co-immunoprecipitation they did observe greater association of CD44 with pERM in 
migrating cells than non-migrating cells. This is something that should be further explored 
in future studies.  
In addition to our investigation of ERM phosphorylation, we next sought to identify 
alternative intracellular mechanisms by which lung-derived selectins may affect breast 
cancer cell migration. This was done using a human phospho-kinase array. When 
comparing the effects of basal media, lung-CM and lung-CM depleted of L-selectin on 
human breast cancer cells, we identified CREB as a potential protein of interest because it 
had the greatest fold change vs. control in its phosphorylation response to lung-CM. Upon 
further analysis, CREB phosphorylation was validated by immunoblotting to be 
significantly elevated in breast cancer cells treated with lung-CM and slightly but non-
significantly reduced upon depletion of a single selectin from lung-CM. Similarly, 
treatment of these cells with recombinant selectin proteins led to a small but non-significant 
increase in CREB phosphorylation relative to the basal media control, leading to the 
conclusion that we were unable to demonstrate a role for selectins in CREB 
phosphorylation. Although previous studies have associated CREB with migration of 
breast cancer cells and hepatocellular carcinoma cells, the observed effect may be through 
other soluble proteins found in lung-CM 118, 119.  
In our phospho-kinase array, another kinase, tyrosine kinase Lyn, was observed to have 
increased phosphorylation in breast cancer cells exposed to lung-CM relative to those 
exposed to basal media. Interestingly, depletion of L-selectin from lung-CM significantly 
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reduced phosphorylation of Lyn.  In the context of human colon cancer, Lyn has been 
implicated as a mediator of cell migration downstream of CD44. Researchers observed that 
CD44 interacted with Lyn and that siRNA knockdown of CD44 in colon cancer cells was 
associated with lower cell migration and Lyn expression relative to the parental cell line120. 
To our knowledge, the role of Lyn kinase downstream of CD44 in breast cancer has not 
been investigated and it is an avenue for our group to investigate further in the future. 
8 Limitations of the Study 
A considerable portion of our study involved an ex vivo model system of the soluble 
lung microenvironment. While it allowed us to easily explore the effects of lung-derived 
selectins on breast cancer cells, there are limitations that should be acknowledged. The first 
is that by examining the effects of soluble lung-derived factors on breast cancer cells in 
isolation, we are ignoring the important contribution that insoluble lung ECM factors and 
other cells of the lung may have on the cancer cells. Studies of small cell lung cancer have 
shown that interaction of the cells with ECM proteins such as fibronectin, laminin and 
collagen IV can both enhance tumorigenicity and confer resistance to chemotherapeutic 
agents121. With respect to the cell-cell interactions, a 2011 study by Qian and colleagues 
demonstrated that the interactions between monocytes and breast cancer cells were 
involved in lung metastasis. They noted that breast cancer cells secreted a chemokine 
capable of activating monocytes that would go on to support cancer cell transmigration122.  
The second limitation of our lung-CM model is that it involves lungs harvested from 
athymic nude mice. Athymic nude mice lack T-cells and lack cell-mediated immunity. This 
impairs their ability to mount robust immune responses, something that is increasingly 
recognized as an important factor in cancer development and progression. For example, 
the number of CD8+ T-cells present in primary breast tumours has been associated with 
better patient survival123. Similarly, a study on non-small-cell lung cancer demonstrated 
that increased infiltration of CD4+ and CD8+ T-cells in lung tumours was associated with 
better patient prognosis as well124. In future investigations, models that take into 
consideration the potential influence of the immune system, cell-ECM and cell-cell 
interactions should be used.  
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The third limitation of the study is the assumption that human breast cancer cells can 
interact with murine lung soluble factors. Generally, it should not be a concern because the 
protein-coding regions of the mouse and human genomes are 85% identical on average125. 
A previous study has also shown that of 4,000 genes examined between humans and mice, 
there are less than ten gene products which exist in one species, but no closely-related form 
exists in the other. Nonetheless, we must express caution in our interpretation of relevance 
to human disease, as exceptions have been shown in the literature where human proteins 
cannot interact with the mouse equivalents of their known binding partners126. 
It is also important to be cognizant of our use of immortalized human breast cancer cell 
lines rather than primary human breast cancer cells. While the cell lines we used are well 
characterized in the literature, they may not fully recapitulate the inherent heterogeneity 
that is seen in the breast cancer patient populations. Researchers previously observed 
differences in the expression of genes related to metabolism and cell communication 
between primary metastatic breast cancer cells and established breast cancer cell lines127. 
To try to minimize concerns of discrepancies, our cells are maintained at low passage 
numbers and routinely authenticated. 
Finally, protein phosphorylation, especially that of ERM, is a dose- and time-dependent 
event128. While we were unable to observe a significant change in ERM phosphorylation 
following cell treatment with different depleted lung-CM, the possibility exists that a 
noticeable effect may occur, but outside of the time window we had examined.   
9 Future Directions 
While this study contributes to our understanding of selectins and the role they may 
play in breast cancer metastasis to the lung, some questions remain unanswered, in 
particular related to the potential intracellular mechanisms by which selectins exert their 
influence on breast cancer cells.  
As mentioned above, binding of CD44 by selectins may not necessarily increase ERM 
protein phosphorylation but could alternatively affect the interaction between p-ERM and 
CD44. By immunofluorescence, we should examine whether ERM proteins and CD44 
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colocalize after cell stimulation with recombinant selectin proteins. To determine if any 
colocalization observed is a result of direct protein interactions, co-immunoprecipitation 
of phosphorylated ERM proteins with CD44 could be examined. These findings could 
allow for more definitive conclusions to be made regarding whether the pro-migratory roles 
of selectins occur via CD44 and ERM. 
Next, we should examine other proteins of interest identified by the phospho-kinase 
array, and in particular, tyrosine kinase Lyn, which has previously been shown to function 
downstream of CD44120. In our experiments with the phospho-kinase array, we observed 
greater phosphorylation of Lyn in response to lung-CM treatment relative to control, and 
the extent of phosphorylation to lung-CM was partially abrogated by L-selectin depletion. 
In future experiments, improved Lyn antibodies for immunoblotting should be used to 
examine the effects of depleting each selectin from lung-CM or blocking CD44 on Lyn 
phosphorylation in breast cancer cells.   
Another idea to explore is whether there is synergy between selectins when 
influencing breast cancer cells. While we have shown the effects of removing selectins 
individually from lung-CM on breast cancer cells, it is unknown as to whether the influence 
on migration would be strengthened further if two or more selectins were depleted. In vivo 
evidence from experimental models of lung metastasis of colon adenocarcinoma suggests 
that L- and P-selectin can function synergistically to enhance metastasis87. In addition to 
studies that examine the effect of depleting lung-CM of multiple selectins, we should 
explore effects of inhibiting selectins with small molecules. Rivipansel (GMI-1070) is a 
pan-selectin inhibitor that is currently in a phase 3 clinical trial for the treatment of vaso-
occlusive crises secondary to sickle cell disease129. Although it is not yet commercially 
available, this drug has been shown to have excellent safety and tolerability in humans130. 
Testing of this drug in our ex vivo model of the lung microenvironment could provide 
valuable preclinical data for Rivipansel’s therapeutic value in the treatment of breast cancer 
metastasis to the lung.  
Although the lung-CM model can be used to provide valuable insight about lung-
derived soluble factors, it does not consider cell to cell and cell to insoluble ECM protein 
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interactions. This can be addressed using a 3D ex vivo model of the lung microenvironment. 
The pulmonary metastasis assay (PuMA) is an ex vivo system in which mouse lungs are 
cut into thin slices (1-2 mm thick) and maintained in culture62, 101, 131. Our lab has 
previously demonstrated that if animals are intravenously injected with breast cancer cells 
15 min prior to euthanasia, this is enough time for tumour cells to be seeded in the lung101. 
By then examining lung slices at different time-points, we can see cancer progression from 
the single cell to micrometastatic to macrometastatic stages. Using the PuMA, we could 
compare tumour progression between breast cancer cells that do or do not express CD44 
in conjunction with comparisons of this in wild-type and selectin-knockout (single or 
multiple selectin deficiency) mice. These experiments could further our understanding of 
the importance of CD44 interactions with lung-derived selectins in breast cancer 
metastasis.   
Finally, since we were unable to identify which forms of each selectin (soluble and/or 
full-length) were present in our lung-CM, we should further examine this using alternative 
approaches. Two different primary antibodies (from different host species) for each 
selectin should be used, one for immunoprecipitation and the other for immunoblotting. By 
using a different primary antibody from different host species such that the secondary 
antibody only interacts with the antibody used for immunoblotting and not co-
immunoprecipitation, we may avoid the interference on our immunoblots that residual co-
immunoprecipitation antibody left in our samples may cause. 
For E-selectin and P-selectin, the molecular weight at which selectins in lung-CM are 
detected should be compared to samples from LPS-activated mouse endothelial cell 
supernatant (for the soluble form) and their cell lysates (membrane bound form), as they 
are appropriate positive controls. For L-selectin isolated from lung-CM, the molecular 
weight observed should be compared with the supernatant of LPS-stimulated neutrophils 
and lysates of untreated neutrophils isolated from mice132. L-selectin is constitutively 
expressed by neutrophils but LPS-stimulation causes L-selectin cleavage from the cell 
surface into its soluble form133. 
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10 Final Conclusions 
It has long been known that breast cancer displays a pattern of preferential metastasis, 
and one common site to which it spreads is the lung. Since breast cancer metastasis to the 
lung is a major contributor to the disease-related mortality, it is important that we elucidate 
why cancer cells preferentially metastasize to the lungs and how we can prevent/treat this 
cancer progression. Using lung-CM as an ex vivo model system, we tested the hypothesis 
that lung-derived selectins promote breast cancer migration and/or growth via interactions 
with CD44. Using our model in conjunction with in vitro transwell migration and BrdU 
incorporation assays, we observed that all three lung-derived selectins promoted the 
migration of breast cancer cells but were not involved in breast cancer cell proliferation. 
By immunoprecipitation, we also demonstrated that CD44 expressed by MDA-MB-231 
human breast cancer cells interacts with selectins and that these interactions may mediate 
the pro-migratory effects observed. Although we were unable to define a pathway by which 
the CD44-selectin interactions may be propagating the signal intracellularly, we did 
identify potential targets of interest and they remain under investigation. Nonetheless, the 
findings of this thesis support the idea of the lung microenvironment playing a role in breast 
cancer metastasis. In accordance with the “seed and soil” theory, targeting the lung 
microenvironment and interfering with factors that would otherwise enhance the metastatic 
behaviour of breast cancer cells could be a potential therapeutic strategy. This approach 
could be feasible for treating lung metastases of breast cancer, as it should be easier to 
target the constant composition of the lung between patients than the highly heterogeneous 
population of cells that make up breast cancer. 
In conclusion, our investigation has provided the foundation for the involvement of 
selectins in lung metastasis of breast cancer. Taken together with further studies, this could 
contribute to improved treatment of breast cancer in the metastatic setting and help reduce 




1. Griffiths, A.;  Miller, J.;  Suzuki, D.;  Lewontin, R.; Gelbart, W., An Introduction 
to Genetic Analysis. 7 ed.; W. H. Freeman: New York, 2000. 
2. Osborne, C.;  Wilson, P.; Tripathy, D., Oncogenes and tumor suppressor genes in 
breast cancer: potential diagnostic and therapeutic applications. Oncologist 2004, 9 (4), 
361-77. 
3. Hanahan, D.; Weinberg, R. A., Hallmarks of cancer: the next generation. Cell 
2011, 144 (5), 646-74. 
4. Cooper, G., The Development and Causes of Cancer. In The Cell: A Molecular 
Approach., 2 ed.; Sinauer Associates: Sunderland (MA), 2000. 
5. Zhang, S. X., Female Reproductive System. In An Atlas of Histology, Springer 
New York: 2013. 
6. Sariego, J., Breast cancer in the young patient. Am Surg 2010, 76 (12), 1397-400. 
7. Chavez-MacGregor, M.;  Elias, S. G.;  Onland-Moret, N. C.;  van der Schouw, Y. 
T.;  Van Gils, C. H.;  Monninkhof, E.;  Grobbee, D. E.; Peeters, P. H., Postmenopausal 
breast cancer risk and cumulative number of menstrual cycles. Cancer Epidemiol 
Biomarkers Prev 2005, 14 (4), 799-804. 
8. Henderson, B. E.; Feigelson, H. S., Hormonal carcinogenesis. Carcinogenesis 
2000, 21 (3), 427-33. 
9. Makki, J., Diversity of Breast Carcinoma: Histological Subtypes and Clinical 
Relevance. Clin Med Insights Pathol 2015, 8, 23-31. 
10. Howlader N, N. A., Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, 
Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. 
SEER Cancer Statistics Review, 1975-2012; National Cancer Institute: Bethesda, MD, 
2014. 
11. Yersal, O.; Barutca, S., Biological subtypes of breast cancer: Prognostic and 
therapeutic implications. World J Clin Oncol 2014, 5 (3), 412-24. 
12. Kennecke, H.;  Yerushalmi, R.;  Woods, R.;  Cheang, M. C.;  Voduc, D.;  Speers, 
C. H.;  Nielsen, T. O.; Gelmon, K., Metastatic behavior of breast cancer subtypes. J Clin 
Oncol 2010, 28 (20), 3271-7. 
13. Valabrega, G.;  Montemurro, F.; Aglietta, M., Trastuzumab: mechanism of action, 
resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 
2007, 18 (6), 977-84. 
51 
 
14. Chambers, A. F.;  Groom, A. C.; MacDonald, I. C., Dissemination and growth of 
cancer cells in metastatic sites. Nature reviews. Cancer 2002, 2 (8), 563-72. 
15. Gómez-Cuadrado, L.;  Tracey, N.;  Ma, R.;  Qian, B.; Brunton, V. G., Mouse 
models of metastasis: progress and prospects. Dis Model Mech 2017, 10 (9), 1061-1074. 
16. Siegel, R. L.;  Miller, K. D.; Jemal, A., Cancer statistics, 2018. CA Cancer J Clin 
2018, 68 (1), 7-30. 
17. Jin, L.;  Han, B.;  Siegel, E.;  Cui, Y.;  Giuliano, A.; Cui, X., Breast cancer lung 
metastasis: Molecular biology and therapeutic implications. Cancer Biol Ther 2018, 1-11. 
18. Heffner, J. E.; Klein, J. S., Recent advances in the diagnosis and management of 
malignant pleural effusions. Mayo Clin Proc 2008, 83 (2), 235-50. 
19. Mitrouska, I.;  Klimathianaki, M.; Siafakas, N. M., Effects of pleural effusion on 
respiratory function. Can Respir J 2004, 11 (7), 499-503. 
20. Heffner, J. E.;  Nietert, P. J.; Barbieri, C., Pleural fluid pH as a predictor of 
survival for patients with malignant pleural effusions. Chest 2000, 117 (1), 79-86. 
21. Chu, J. E.; Allan, A. L., The Role of Cancer Stem Cells in the Organ Tropism of 
Breast Cancer Metastasis: A Mechanistic Balance between the "Seed" and the "Soil"? Int 
J Breast Cancer 2012, 2012, 209748. 
22. Hess, K. R.;  Varadhachary, G. R.;  Taylor, S. H.;  Wei, W.;  Raber, M. N.;  
Lenzi, R.; Abbruzzese, J. L., Metastatic patterns in adenocarcinoma. Cancer 2006, 106 
(7), 1624-33. 
23. Paget, S., The distribution of secondary growths in cancer of the breast. 1889. 
Cancer Metastasis Rev 1889, 8 (2), 98-101. 
24. Ribatti, D.;  Mangialardi, G.; Vacca, A., Stephen Paget and the 'seed and soil' 
theory of metastatic dissemination. Clin Exp Med 2006, 6 (4), 145-9. 
25. Chu, J. E.;  Xia, Y.;  Chin-Yee, B.;  Goodale, D.;  Croker, A. K.; Allan, A. L., 
Lung-Derived Factors Mediate Breast Cancer Cell Migration through CD44 Receptor-
Ligand Interactions in a Novel Ex Vivo System for Analysis of Organ-Specific Soluble 
Proteins. Neoplasia 2014, 16 (2), 180-IN27. 
26. Bos, P. D.;  Zhang, X. H.;  Nadal, C.;  Shu, W.;  Gomis, R. R.;  Nguyen, D. X.;  
Minn, A. J.;  van de Vijver, M. J.;  Gerald, W. L.;  Foekens, J. A.; Massagué, J., Genes 
that mediate breast cancer metastasis to the brain. Nature 2009, 459 (7249), 1005-9. 
27. Kang, Y.;  Siegel, P. M.;  Shu, W.;  Drobnjak, M.;  Kakonen, S. M.;  Cordón-
Cardo, C.;  Guise, T. A.; Massagué, J., A multigenic program mediating breast cancer 
metastasis to bone. Cancer Cell 2003, 3 (6), 537-49. 
52 
 
28. Minn, A. J.;  Gupta, G. P.;  Siegel, P. M.;  Bos, P. D.;  Shu, W.;  Giri, D. D.;  
Viale, A.;  Olshen, A. B.;  Gerald, W. L.; Massagué, J., Genes that mediate breast cancer 
metastasis to lung. Nature 2005, 436 (7050), 518-24. 
29. Minn, A. J.;  Gupta, G. P.;  Padua, D.;  Bos, P.;  Nguyen, D. X.;  Nuyten, D.;  
Kreike, B.;  Zhang, Y.;  Wang, Y.;  Ishwaran, H.;  Foekens, J. A.;  van de Vijver, M.; 
Massagué, J., Lung metastasis genes couple breast tumor size and metastatic spread. Proc 
Natl Acad Sci U S A 2007, 104 (16), 6740-5. 
30. O'Brien, C. A.;  Kreso, A.; Dick, J. E., Cancer stem cells in solid tumors: an 
overview. Semin Radiat Oncol 2009, 19 (2), 71-7. 
31. Shiozawa, Y.;  Nie, B.;  Pienta, K. J.;  Morgan, T. M.; Taichman, R. S., Cancer 
stem cells and their role in metastasis. Pharmacol Ther 2013, 138 (2), 285-93. 
32. Bonnet, D.; Dick, J. E., Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3 (7), 730-7. 
33. Visvader, J. E.; Lindeman, G. J., Cancer stem cells in solid tumours: 
accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8 (10), 755-68. 
34. Al-Hajj, M.;  Wicha, M. S.;  Benito-Hernandez, A.;  Morrison, S. J.; Clarke, M. 
F., Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S 
A 2003, 100 (7), 3983-8. 
35. Ginestier, C.;  Hur, M. H.;  Charafe-Jauffret, E.;  Monville, F.;  Dutcher, J.;  
Brown, M.;  Jacquemier, J.;  Viens, P.;  Kleer, C. G.;  Liu, S.;  Schott, A.;  Hayes, D.;  
Birnbaum, D.;  Wicha, M. S.; Dontu, G., ALDH1 is a marker of normal and malignant 
human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 
2007, 1 (5), 555-67. 
36. Sophos, N. A.; Vasiliou, V., Aldehyde dehydrogenase gene superfamily: the 2002 
update. Chem Biol Interact 2003, 143-144, 5-22. 
37. Chute, J. P.;  Muramoto, G. G.;  Whitesides, J.;  Colvin, M.;  Safi, R.;  Chao, N. 
J.; McDonnell, D. P., Inhibition of aldehyde dehydrogenase and retinoid signaling 
induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A 
2006, 103 (31), 11707-12. 
38. Croker, A. K.;  Goodale, D.;  Chu, J.;  Postenka, C.;  Hedley, B. D.;  Hess, D. A.; 
Allan, A. L., High aldehyde dehydrogenase and expression of cancer stem cell markers 
selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol 
Med 2009, 13 (8B), 2236-52. 
39. Louderbough, J. M.; Schroeder, J. A., Understanding the dual nature of CD44 in 
breast cancer progression. Mol Cancer Res 2011, 9 (12), 1573-86. 
53 
 
40. Naor, D.;  Sionov, R. V.; Ish-Shalom, D., CD44: structure, function, and 
association with the malignant process. Adv Cancer Res 1997, 71, 241-319. 
41. Ponta, H.;  Wainwright, D.; Herrlich, P., The CD44 protein family. Int J Biochem 
Cell Biol 1998, 30 (3), 299-305. 
42. Legg, J. W.;  Lewis, C. A.;  Parsons, M.;  Ng, T.; Isacke, C. M., A novel PKC-
regulated mechanism controls CD44 ezrin association and directional cell motility. Nat 
Cell Biol 2002, 4 (6), 399-407. 
43. Orian-Rousseau, V.;  Chen, L.;  Sleeman, J. P.;  Herrlich, P.; Ponta, H., CD44 is 
required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002, 16 (23), 
3074-86. 
44. Naor, D.;  Nedvetzki, S.;  Golan, I.;  Melnik, L.; Faitelson, Y., CD44 in cancer. 
Crit Rev Clin Lab Sci 2002, 39 (6), 527-79. 
45. Cho, Y.;  Lee, H. W.;  Kang, H. G.;  Kim, H. Y.;  Kim, S. J.; Chun, K. H., 
Cleaved CD44 intracellular domain supports activation of stemness factors and promotes 
tumorigenesis of breast cancer. Oncotarget 2015, 6 (11), 8709-21. 
46. Ponta, H.;  Sherman, L.; Herrlich, P. A., CD44: from adhesion molecules to 
signalling regulators. Nat Rev Mol Cell Biol 2003, 4 (1), 33-45. 
47. Crepaldi, T.;  Gautreau, A.;  Comoglio, P. M.;  Louvard, D.; Arpin, M., Ezrin is 
an effector of hepatocyte growth factor-mediated migration and morphogenesis in 
epithelial cells. J Cell Biol 1997, 138 (2), 423-34. 
48. Ng, T.;  Parsons, M.;  Hughes, W. E.;  Monypenny, J.;  Zicha, D.;  Gautreau, A.;  
Arpin, M.;  Gschmeissner, S.;  Verveer, P. J.;  Bastiaens, P. I.; Parker, P. J., Ezrin is a 
downstream effector of trafficking PKC-integrin complexes involved in the control of 
cell motility. EMBO J 2001, 20 (11), 2723-41. 
49. Mackay, C. R.;  Terpe, H. J.;  Stauder, R.;  Marston, W. L.;  Stark, H.; Günthert, 
U., Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994, 
124 (1-2), 71-82. 
50. Lesley, J.;  Hascall, V. C.;  Tammi, M.; Hyman, R., Hyaluronan binding by cell 
surface CD44. J Biol Chem 2000, 275 (35), 26967-75. 
51. Weber, G. F.;  Ashkar, S.;  Glimcher, M. J.; Cantor, H., Receptor-ligand 
interaction between CD44 and osteopontin (Eta-1). Science 1996, 271 (5248), 509-12. 
52. Toyama-Sorimachi, N.;  Sorimachi, H.;  Tobita, Y.;  Kitamura, F.;  Yagita, H.;  
Suzuki, K.; Miyasaka, M., A novel ligand for CD44 is serglycin, a hematopoietic cell 
lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and 
activation. J Biol Chem 1995, 270 (13), 7437-44. 
54 
 
53. Dimitroff, C. J.;  Lee, J. Y.;  Rafii, S.;  Fuhlbrigge, R. C.; Sackstein, R., CD44 is a 
major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 2001, 153 
(6), 1277-86. 
54. Dimitroff, C. J.;  Lee, J. Y.;  Fuhlbrigge, R. C.; Sackstein, R., A distinct 
glycoform of CD44 is an L-selectin ligand on human hematopoietic cells. Proc Natl Acad 
Sci U S A 2000, 97 (25), 13841-6. 
55. Alves, C. S.;  Burdick, M. M.;  Thomas, S. N.;  Pawar, P.; Konstantopoulos, K., 
The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon 
carcinoma cell adhesion. Am J Physiol Cell Physiol 2008, 294 (4), C907-16. 
56. Olsson, E.;  Honeth, G.;  Bendahl, P. O.;  Saal, L. H.;  Gruvberger-Saal, S.;  
Ringnér, M.;  Vallon-Christersson, J.;  Jönsson, G.;  Holm, K.;  Lövgren, K.;  Fernö, M.;  
Grabau, D.;  Borg, A.; Hegardt, C., CD44 isoforms are heterogeneously expressed in 
breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC 
Cancer 2011, 11, 418. 
57. Afify, A.;  Purnell, P.; Nguyen, L., Role of CD44s and CD44v6 on human breast 
cancer cell adhesion, migration, and invasion. Exp Mol Pathol 2009, 86 (2), 95-100. 
58. Fidler, I. J., Metastasis: quantitative analysis of distribution and fate of tumor 
emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst 1970, 45 (4), 773-
82. 
59. Fidler, I. J., Orthotopic implantation of human colon carcinomas into nude mice 
provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis 
Rev 1991, 10 (3), 229-43. 
60. Pio, G. M.;  Xia, Y.;  Piaseczny, M. M.;  Chu, J. E.; Allan, A. L., Soluble bone-
derived osteopontin promotes migration and stem-like behavior of breast cancer cells. 
PLoS One 2017, 12 (5), e0177640. 
61. Piaseczny, M. M.;  Pio, G. M.;  Chu, J. E.;  Xia, Y.;  Nguyen, K.;  Goodale, D.; 
Allan, A., Generation of Organ-conditioned Media and Applications for Studying Organ-
specific Influences on Breast Cancer Metastatic Behavior. J Vis Exp 2016,  (112). 
62. Piaseczny, M.;  Goodale, D.; Allan, A., The lung microenvironment influences 
the metastatic behavior of breast cancer cells in an innovative 3D ex vivo pulmonary 
metastasis model [abstract]. In Proceedings of the 106th Annual Meeting of the American 
Association for Cancer Research, AACR: Philadelphia, PA., 2015; Vol. 2015;75(15 
Suppl). 
63. Ley, K., The role of selectins in inflammation and disease. Trends Mol Med 2003, 
9 (6), 263-8. 
64. Natoni, A.;  Macauley, M. S.; O'Dwyer, M. E., Targeting Selectins and Their 
Ligands in Cancer. Front Oncol 2016, 6, 93. 
55 
 
65. Lee, D.;  Schultz, J. B.;  Knauf, P. A.; King, M. R., Mechanical shedding of L-
selectin from the neutrophil surface during rolling on sialyl Lewis x under flow. J Biol 
Chem 2007, 282 (7), 4812-20. 
66. Bendas, G.; Borsig, L., Cancer cell adhesion and metastasis: selectins, integrins, 
and the inhibitory potential of heparins. Int J Cell Biol 2012, 2012, 676731. 
67. Bevilacqua, M. P.;  Pober, J. S.;  Mendrick, D. L.;  Cotran, R. S.; Gimbrone, M. 
A., Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl 
Acad Sci U S A 1987, 84 (24), 9238-42. 
68. Dunlop, L. C.;  Skinner, M. P.;  Bendall, L. J.;  Favaloro, E. J.;  Castaldi, P. A.;  
Gorman, J. J.;  Gamble, J. R.;  Vadas, M. A.; Berndt, M. C., Characterization of GMP-
140 (P-selectin) as a circulating plasma protein. J Exp Med 1992, 175 (4), 1147-50. 
69. Kahn, J.;  Ingraham, R. H.;  Shirley, F.;  Migaki, G. I.; Kishimoto, T. K., 
Membrane proximal cleavage of L-selectin: identification of the cleavage site and a 6-kD 
transmembrane peptide fragment of L-selectin. J Cell Biol 1994, 125 (2), 461-70. 
70. Newman, W.;  Beall, L. D.;  Carson, C. W.;  Hunder, G. G.;  Graben, N.;  
Randhawa, Z. I.;  Gopal, T. V.;  Wiener-Kronish, J.; Matthay, M. A., Soluble E-selectin 
is found in supernatants of activated endothelial cells and is elevated in the serum of 
patients with septic shock. J Immunol 1993, 150 (2), 644-54. 
71. Kapupara, K.;  Wen, Y. T.;  Tsai, R. K.; Huang, S. P., Soluble P-selectin 
promotes retinal ganglion cell survival through activation of Nrf2 signaling after 
ischemia injury. Cell Death Dis 2017, 8 (11), e3172. 
72. Kumar, P.;  Hosaka, S.; Koch, A. E., Soluble E-selectin induces monocyte 
chemotaxis through Src family tyrosine kinases. J Biol Chem 2001, 276 (24), 21039-45. 
73. Schleiffenbaum, B.;  Spertini, O.; Tedder, T. F., Soluble L-selectin is present in 
human plasma at high levels and retains functional activity. J Cell Biol 1992, 119 (1), 
229-38. 
74. Chen, A. Y.;  Ha, J. N.;  Delano, F. A.; Schmid-Schönbein, G. W., Receptor 
cleavage and P-selectin-dependent reduction of leukocyte adhesion in the spontaneously 
hypertensive rat. J Leukoc Biol 2012, 92 (1), 183-94. 
75. Sheen-Chen, S. M.;  Eng, H. L.;  Huang, C. C.; Chen, W. J., Serum levels of 
soluble E-selectin in women with breast cancer. Br J Surg 2004, 91 (12), 1578-81. 
76. Silva, H. C.;  Garcao, F.;  Coutinho, E. C.;  De Oliveira, C. F.; Regateiro, F. J., 
Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the 
detection of circulating cancer cells. Neoplasma 2006, 53 (6), 538-43. 
77. Hebbar, M.; Peyrat, J. P., Significance of soluble endothelial molecule E-selectin 
in patients with breast cancer. Int J Biol Markers 2000, 15 (1), 15-21. 
56 
 
78. Hebbar, M.;  Krzewinski-Recchi, M. A.;  Hornez, L.;  Verdière, A.;  Harduin-
Lepers, A.;  Bonneterre, J.;  Delannoy, P.; Peyrat, J. P., Prognostic value of tumoral 
sialyltransferase expression and circulating E-selectin concentrations in node-negative 
breast cancer patients. Int J Biol Markers 2003, 18 (2), 116-22. 
79. Revelle, B. M.;  Scott, D.; Beck, P. J., Single amino acid residues in the E- and P-
selectin epidermal growth factor domains can determine carbohydrate binding specificity. 
J Biol Chem 1996, 271 (27), 16160-70. 
80. Kontogianni, P.;  Zambirinis, C. P.;  Theodoropoulos, G.;  Gazouli, M.;  
Michalopoulos, N. V.;  Flessas, J.;  Liberi, M.; Zografos, G. C., The impact of the stromal 
cell-derived factor-1-3'A and E-selectin S128R polymorphisms on breast cancer. Mol 
Biol Rep 2013, 40 (1), 43-50. 
81. Extermann, M.;  Bacchi, M.;  Monai, N.;  Fopp, M.;  Fey, M.;  Tichelli, A.;  
Schapira, M.; Spertini, O., Relationship between cleaved L-selectin levels and the 
outcome of acute myeloid leukemia. Blood 1998, 92 (9), 3115-22. 
82. Choudhary, D.;  Hegde, P.;  Voznesensky, O.;  Choudhary, S.;  Kopsiaftis, S.;  
Claffey, K. P.;  Pilbeam, C. C.; Taylor, J. A., Increased expression of L-selectin (CD62L) 
in high-grade urothelial carcinoma: A potential marker for metastatic disease. Urol Oncol 
2015, 33 (9), 387.e17-27. 
83. Blann, A. D.;  Gurney, D.;  Wadley, M.;  Bareford, D.;  Stonelake, P.; Lip, G. Y., 
Increased soluble P-selectin in patients with haematological and breast cancer: a 
comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. 
Blood Coagul Fibrinolysis 2001, 12 (1), 43-50. 
84. Dymicka-Piekarska, V.; Kemona, H., Does colorectal cancer clinical 
advancement affect adhesion molecules (sP-selectin, sE-selectin and ICAM-1) 
concentration? Thromb Res 2009, 124 (1), 80-3. 
85. Robinson, S. D.;  Frenette, P. S.;  Rayburn, H.;  Cummiskey, M.;  Ullman-
Culleré, M.;  Wagner, D. D.; Hynes, R. O., Multiple, targeted deficiencies in selectins 
reveal a predominant role for P-selectin in leukocyte recruitment. Proc Natl Acad Sci U S 
A 1999, 96 (20), 11452-7. 
86. Stübke, K.;  Wicklein, D.;  Herich, L.;  Schumacher, U.; Nehmann, N., Selectin-
deficiency reduces the number of spontaneous metastases in a xenograft model of human 
breast cancer. Cancer Lett 2012, 321 (1), 89-99. 
87. Borsig, L.;  Wong, R.;  Hynes, R. O.;  Varki, N. M.; Varki, A., Synergistic effects 
of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and 




88. Hanley, W. D.;  Napier, S. L.;  Burdick, M. M.;  Schnaar, R. L.;  Sackstein, R.; 
Konstantopoulos, K., Variant isoforms of CD44 are P- and L-selectin ligands on colon 
carcinoma cells. FASEB J 2006, 20 (2), 337-9. 
89. Shirure, V. S.;  Liu, T.;  Delgadillo, L. F.;  Cuckler, C. M.;  Tees, D. F.;  
Benencia, F.;  Goetz, D. J.; Burdick, M. M., CD44 variant isoforms expressed by breast 
cancer cells are functional E-selectin ligands under flow conditions. Am J Physiol Cell 
Physiol 2015, 308 (1), C68-78. 
90. Ley, K.;  Laudanna, C.;  Cybulsky, M. I.; Nourshargh, S., Getting to the site of 
inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7 (9), 
678-89. 
91. Arpin, M.;  Chirivino, D.;  Naba, A.; Zwaenepoel, I., Emerging role for ERM 
proteins in cell adhesion and migration. Cell Adh Migr 2011, 5 (2), 199-206. 
92. Brown, K. L.;  Birkenhead, D.;  Lai, J. C.;  Li, L.;  Li, R.; Johnson, P., Regulation 
of hyaluronan binding by F-actin and colocalization of CD44 and phosphorylated 
ezrin/radixin/moesin (ERM) proteins in myeloid cells. Exp Cell Res 2005, 303 (2), 400-
14. 
93. Babina, I. S.;  McSherry, E. A.;  Donatello, S.;  Hill, A. D.; Hopkins, A. M., A 
novel mechanism of regulating breast cancer cell migration via palmitoylation-dependent 
alterations in the lipid raft affiliation of CD44. Breast Cancer Res 2014, 16 (1), R19. 
94. Breast cancer statistics. (accessed August 20). 
95. Holen, I.;  Speirs, V.;  Morrissey, B.; Blyth, K., models in breast cancer research: 
progress, challenges and future directions. Dis Model Mech 2017, 10 (4), 359-371. 
96. Davies, C.;  Godwin, J.;  Gray, R.;  Clarke, M.;  Cutter, D.;  Darby, S.;  McGale, 
P.;  Pan, H. C.;  Taylor, C.;  Wang, Y. C.;  Dowsett, M.;  Ingle, J.;  Peto, R.; (EBCTCG), 
E. B. C. T. C. G., Relevance of breast cancer hormone receptors and other factors to the 
efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 
2011, 378 (9793), 771-84. 
97. Perez, E. A.;  Romond, E. H.;  Suman, V. J.;  Jeong, J. H.;  Sledge, G.;  Geyer, C. 
E.;  Martino, S.;  Rastogi, P.;  Gralow, J.;  Swain, S. M.;  Winer, E. P.;  Colon-Otero, G.;  
Davidson, N. E.;  Mamounas, E.;  Zujewski, J. A.; Wolmark, N., Trastuzumab plus 
adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast 
cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. 
J Clin Oncol 2014, 32 (33), 3744-52. 
98. Tabar, L.;  Yen, M. F.;  Vitak, B.;  Chen, H. H.;  Smith, R. A.; Duffy, S. W., 
Mammography service screening and mortality in breast cancer patients: 20-year follow-
up before and after introduction of screening. Lancet 2003, 361 (9367), 1405-10. 
58 
 
99. Kalimutho, M.;  Parsons, K.;  Mittal, D.;  López, J. A.;  Srihari, S.; Khanna, K. K., 
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. 
Trends Pharmacol Sci 2015, 36 (12), 822-846. 
100. Bennett, K. L.;  Jackson, D. G.;  Simon, J. C.;  Tanczos, E.;  Peach, R.;  Modrell, 
B.;  Stamenkovic, I.;  Plowman, G.; Aruffo, A., CD44 isoforms containing exon V3 are 
responsible for the presentation of heparin-binding growth factor. J Cell Biol 1995, 128 
(4), 687-98. 
101. Piaseczny, M. M. The lung microenvironment influences the metastatic behaviour 
of breast cancer cells in an innovative 3D ex vivo pulmonary metastasis model. 
University of Western Ontario, Electronic Thesis and Dissertation Repository, 2015. 
102. Jiang, M.;  Xu, X.;  Bi, Y.;  Xu, J.;  Qin, C.; Han, M., Systemic inflammation 
promotes lung metastasis via E-selectin upregulation in mouse breast cancer model. 
Cancer Biol Ther 2014, 15 (6), 789-96. 
103. Kim, Y. J.;  Borsig, L.;  Varki, N. M.; Varki, A., P-selectin deficiency attenuates 
tumor growth and metastasis. Proc Natl Acad Sci U S A 1998, 95 (16), 9325-30. 
104. Ulich, T. R.;  Howard, S. C.;  Remick, D. G.;  Yi, E. S.;  Collins, T.;  Guo, K.;  
Yin, S.;  Keene, J. L.;  Schmuke, J. J.; Steininger, C. N., Intratracheal administration of 
endotoxin and cytokines: VIII. LPS induces E-selectin expression; anti-E-selectin and 
soluble E-selectin inhibit acute inflammation. Inflammation 1994, 18 (4), 389-98. 
105. Lobb, R. R.;  Chi-Rosso, G.;  Leone, D. R.;  Rosa, M. D.;  Bixler, S.;  Newman, 
B. M.;  Luhowskyj, S.;  Benjamin, C. D.;  Dougas, I. G.; Goelz, S. E., Expression and 
functional characterization of a soluble form of endothelial-leukocyte adhesion molecule 
1. J Immunol 1991, 147 (1), 124-9. 
106. Gamble, J. R.;  Skinner, M. P.;  Berndt, M. C.; Vadas, M. A., Prevention of 
activated neutrophil adhesion to endothelium by soluble adhesion protein GMP140. 
Science 1990, 249 (4967), 414-7. 
107. Nam, K.;  Oh, S.;  Lee, K. M.;  Yoo, S. A.; Shin, I., CD44 regulates cell 
proliferation, migration, and invasion via modulation of c-Src transcription in human 
breast cancer cells. Cell Signal 2015, 27 (9), 1882-94. 
108. Kang, S. A.;  Blache, C. A.;  Bajana, S.;  Hasan, N.;  Kamal, M.;  Morita, Y.;  
Gupta, V.;  Tsolmon, B.;  Suh, K. S.;  Gorenstein, D. G.;  Razaq, W.;  Rui, H.; Tanaka, 
T., The effect of soluble E-selectin on tumor progression and metastasis. BMC Cancer 
2016, 16, 331. 
109. Subramaniam, M.;  Saffaripour, S.;  Watson, S. R.;  Mayadas, T. N.;  Hynes, R. 
O.; Wagner, D. D., Reduced recruitment of inflammatory cells in a contact 
hypersensitivity response in P-selectin-deficient mice. J Exp Med 1995, 181 (6), 2277-82. 
59 
 
110. Coupland, L. A.;  Chong, B. H.; Parish, C. R., Platelets and P-selectin control 
tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer 
Res 2012, 72 (18), 4662-71. 
111. Morbidelli, L.;  Brogelli, L.;  Granger, H. J.; Ziche, M., Endothelial cell migration 
is induced by soluble P-selectin. Life Sci 1998, 62 (1), PL7-11. 
112. Hanley, W. D.;  Burdick, M. M.;  Konstantopoulos, K.; Sackstein, R., CD44 on 
LS174T colon carcinoma cells possesses E-selectin ligand activity. Cancer Res 2005, 65 
(13), 5812-7. 
113. Kang, S. A.;  Hasan, N.;  Mann, A. P.;  Zheng, W.;  Zhao, L.;  Morris, L.;  Zhu, 
W.;  Zhao, Y. D.;  Suh, K. S.;  Dooley, W. C.;  Volk, D.;  Gorenstein, D. G.;  
Cristofanilli, M.;  Rui, H.; Tanaka, T., Blocking the adhesion cascade at the premetastatic 
niche for prevention of breast cancer metastasis. Mol Ther 2015, 23 (6), 1044-1054. 
114. Li, Y.;  Harada, T.;  Juang, Y. T.;  Kyttaris, V. C.;  Wang, Y.;  Zidanic, M.;  Tung, 
K.; Tsokos, G. C., Phosphorylated ERM is responsible for increased T cell polarization, 
adhesion, and migration in patients with systemic lupus erythematosus. J Immunol 2007, 
178 (3), 1938-47. 
115. Martin, T. A.;  Harrison, G.;  Mansel, R. E.; Jiang, W. G., The role of the 
CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003, 46 (2), 165-86. 
116. Gary, R.; Bretscher, A., Ezrin self-association involves binding of an N-terminal 
domain to a normally masked C-terminal domain that includes the F-actin binding site. 
Mol Biol Cell 1995, 6 (8), 1061-75. 
117. Donatello, S.;  Babina, I. S.;  Hazelwood, L. D.;  Hill, A. D.;  Nabi, I. R.; 
Hopkins, A. M., Lipid raft association restricts CD44-ezrin interaction and promotion of 
breast cancer cell migration. Am J Pathol 2012, 181 (6), 2172-87. 
118. Singh, R.;  Shankar, B. S.; Sainis, K. B., TGF-β1-ROS-ATM-CREB signaling 
axis in macrophage mediated migration of human breast cancer MCF7 cells. Cell Signal 
2014, 26 (7), 1604-15. 
119. Yang, Z.;  Tsuchiya, H.;  Zhang, Y.;  Hartnett, M. E.; Wang, L., MicroRNA-433 
inhibits liver cancer cell migration by repressing the protein expression and function of 
cAMP response element-binding protein. J Biol Chem 2013, 288 (40), 28893-9. 
120. Subramaniam, V.;  Vincent, I. R.;  Gardner, H.;  Chan, E.;  Dhamko, H.; Jothy, S., 
CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT 
phosphorylation. Exp Mol Pathol 2007, 83 (2), 207-15. 
121. Rintoul, R. C.; Sethi, T., Extracellular matrix regulation of drug resistance in 
small-cell lung cancer. Clin Sci (Lond) 2002, 102 (4), 417-24. 
60 
 
122. Qian, B. Z.;  Li, J.;  Zhang, H.;  Kitamura, T.;  Zhang, J.;  Campion, L. R.;  
Kaiser, E. A.;  Snyder, L. A.; Pollard, J. W., CCL2 recruits inflammatory monocytes to 
facilitate breast-tumour metastasis. Nature 2011, 475 (7355), 222-5. 
123. Mahmoud, S. M.;  Paish, E. C.;  Powe, D. G.;  Macmillan, R. D.;  Grainge, M. J.;  
Lee, A. H.;  Ellis, I. O.; Green, A. R., Tumor-infiltrating CD8+ lymphocytes predict 
clinical outcome in breast cancer. J Clin Oncol 2011, 29 (15), 1949-55. 
124. Hiraoka, K.;  Miyamoto, M.;  Cho, Y.;  Suzuoki, M.;  Oshikiri, T.;  Nakakubo, Y.;  
Itoh, T.;  Ohbuchi, T.;  Kondo, S.; Katoh, H., Concurrent infiltration by CD8+ T cells and 
CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J 
Cancer 2006, 94 (2), 275-80. 
125. Why Mouse Matters. Mouse  Sequencing Consortium 2010, 
https://www.genome.gov/10001345/importance-of-mouse-genome/. 
126. Chen, W.;  Zhou, Z.;  Li, L.;  Zhong, C. Q.;  Zheng, X.;  Wu, X.;  Zhang, Y.;  Ma, 
H.;  Huang, D.;  Li, W.;  Xia, Z.; Han, J., Diverse sequence determinants control human 
and mouse receptor interacting protein 3 (RIP3) and mixed lineage kinase domain-like 
(MLKL) interaction in necroptotic signaling. J Biol Chem 2013, 288 (23), 16247-61. 
127. Fernandez-Cobo, M.;  Holland, J. F.; Pogo, B. G., Transcription profiles of non-
immortalized breast cancer cell lines. BMC Cancer 2006, 6, 99. 
128. Huang, H.;  Xiao, Y.;  Lin, H.;  Fu, D.;  Zhan, Z.;  Liang, L.;  Yang, X.;  Fan, J.;  
Ye, Y.;  Sun, L.; Xu, H., Increased phosphorylation of ezrin/radixin/moesin proteins 
contributes to proliferation of rheumatoid fibroblast-like synoviocytes. Rheumatology 
(Oxford) 2011, 50 (6), 1045-53. 
129. Pfizer. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 
Parallel-group Study To Evaluate The Efficacy And Safety Of Rivipansel (Gmi-1070) In 
The Treatment Of Vaso-occlusive Crisis In Hospitalized Subjects With Sickle Cell 
Disease (2015). https://clinicaltrials.gov/ct2/ (Identification No. NCT02187003) 
(accessed August 20, 2018). 
130. Telen, M. J.;  Wun, T.;  McCavit, T. L.;  De Castro, L. M.;  Krishnamurti, L.;  
Lanzkron, S.;  Hsu, L. L.;  Smith, W. R.;  Rhee, S.;  Magnani, J. L.; Thackray, H., 
Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-
occlusive events and decreased opioid use. Blood 2015, 125 (17), 2656-64. 
131. Mendoza, A.;  Hong, S. H.;  Osborne, T.;  Khan, M. A.;  Campbell, K.;  Briggs, 
J.;  Eleswarapu, A.;  Buquo, L.;  Ren, L.;  Hewitt, S. M.;  Dakir, e. H.;  Dakir, e.-H.;  
Garfield, S.;  Walker, R.;  Merlino, G.;  Green, J. E.;  Hunter, K. W.;  Wakefield, L. M.; 
Khanna, C., Modeling metastasis biology and therapy in real time in the mouse lung. J 
Clin Invest 2010, 120 (8), 2979-88. 
132. Bennett, T. A.;  Lynam, E. B.;  Sklar, L. A.; Rogelj, S., Hydroxamate-based 
metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from 
61 
 
leukocytes: functional consequences for neutrophil aggregation. J Immunol 1996, 156 
(9), 3093-7. 
133. Smalley, D. M.; Ley, K., L-selectin: mechanisms and physiological significance 












Appendix 2: Immunoblotting analysis of immunoprecipitated selectins from lung-CM. 
Lysates from normal and activated mouse pulmonary vein endothelial cells (EC) were used 
as positive controls for E-selectin and P-selectin. Lysates from primary mouse leukocytes 
were used as a positive control for L-selectin. (A) Immunoblot analysis of E-selectin 
immunoprecipitated samples from lung-CM revealed 2 bands: one at 75 kDa and another 
at approximately 65 kDa. These two bands were not observed in the IgG control. For the 
positive control of mouse pulmonary vein endothelial cells (MPVEC), both the untreated 
and those activated by lipopolysaccharide (LPS) treatment displayed numerous bands 
when subject to immunoblotting. A specific molecular size for E-selectin could therefore 
not be inferred from the MPVEC. (B) Immunoblot analysis of L-selectin 
immunoprecipitated from lung-CM revealed non-specific binding and no differences in 
banding pattern relative to the IgG control. A positive control of leukocytes isolated from 
the blood of female nude athymic mice revealed a band at approximately 45 kDa in size. 
This region is at the same molecular size as IgG heavy chains (~50 kDa) that were 
otherwise strongly stained for in immunoprecipitated samples, suggesting a masking of 
this band in the immunoprecipitated samples. (C) Similarly, immunoblot analysis of P-
selectin immunoprecipitated from lung-CM revealed non-specific binding and no 
differences in banding pattern relative to the IgG control. However, a set of two bands at 
approximately 45 kDa were observed in immunoblots of untreated and activated 
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